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Abstract 
This thesis describes and investigates novel strategies for cysteine modification to 
achieve protein bioconjugation.  Chapter 1 provides an introduction to the research 
project with an overview of protein modification techniques. Chapter 2 describes the 
development of a site selective dual labelling strategy based on substrate controlled 
cysteine modification. The application of this strategy to green fluorescent protein is 
also detailed. Chapter 3 describes the development and evaluation of 
thiophosphonium as a platform for protein modification. An in-depth discussion on 
reaction mechanisms, pathways, stability of thiophosphonium and the utility of this 
platform is also included. Chapter 4 describes the development of bromomaleimide 
based reversible cysteine modification, with particular focus on development of 
improved strategies for conversion of thiomaleimides back to free cysteines. The 
utility of the approach was demonstrated using a proof of concept experiment.  
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Chapter 1 Introduction 
1.1 Chemical modification of proteins 
Decoding the chemistry of life is the ultimate goal for biochemists and chemical 
biologists. The enormous complexity of chemical and biochemical pathways 
represents a major obstacle towards achieving this aim. A significant step in this 
direction was the decoding of the entire human genome sequence, which provided a 
vast trove of genetic information.
1,2
 Whilst the human genome consists of 25000-
30000 genes,
1
 the human proteome is much more complex, consisting of more than 1 
million proteins.
3
 It is essential, therefore, to understand the functions of encoded 
proteins to gain a thorough understanding of the chemistry of life.
4
  While different 
mRNA transcripts can be generated from a single gene, the true complexity of the 
human proteome is generated following translation by covalent processing events 
that change the properties of a protein by proteolytic cleavage or by addition of a 
modifying group to one or more amino acids.
5
 These chemical changes, referred to as 
‘Post-Translational Modifications’ (PTMs), often fundamentally alter the innate 
protein function,
6
 e.g. phosphorylation of serine causes conformational switches to  
(de)activate protein-protein interactions,
7
 ubiquitination generally marks proteins for 
degradation by 26S proteasome,
8
 and acetylation of lysine regulates DNA-protein 
interaction for histones (Figure 1).
9
   
 
Figure 1 : Phosphorylated serine and N-Acetylated lysine 
Consequently, understanding PTMs is hugely significant as it provides invaluable 
insight into cellular functions and processes. The major challenge in this area is to 
gain access to post-translationally modified proteins.  
2 
Advances in protein modification methods have led to the development of a range of 
protein bioconjugation technologies and their application in a range of fields such as 
the imaging of proteins by fluorescent tagging to track proteins in vitro and in vivo
10
 
and the development of therapeutic protein conjugates
11,12
 to treat indications such as 
HIV,
13
 cancer,
14
 and malaria.
15
 Chemically modified proteins also find applications 
in diagnostics.
16
  
Despite these advances, synthetic methodology to access PTMs by developing 
synthetic mimics is highly desired.
17,18 
The use of synthetic methodology to modify 
proteins faces some major challenges, the most significant of which is the need for 
high selectivity and precision, for example, discrimination against the 20 natural 
amino acids is essential for selective modification.
19
 Moreover, these modifications 
must be carried out in aqueous media, near physiological pH and at ambient 
temperature to prevent denaturing of proteins. In addition, these reactions should be 
unaffected by surfactants that are often required for protein stability.
20
 Despite these 
challenges, over the years a large number of approaches to protein modification have 
been developed.
21,22
 Whilst some of these approaches rely on novel reactions 
designed to work with high specificity, other approaches have relied on expanding 
the genetic code and introducing unnatural amino acids for site selective 
modification.
23
   
This chapter provides an introduction to the various approaches available for protein 
modification and also outlines the challenges currently being faced. Brief 
introductory sections are provided at the start of subsequent chapters to place the 
work described into context. 
1.2 Protein modification approaches 
A plethora of methods for protein modification have been reported over the last 
decade. These approaches can be divided into two major categories: modification of 
natural amino acids and modification of non-natural amino acids. Each of these 
methods have their own unique advantages and disadvantages and are described in 
further detail below. 
3 
1.2.1 Natural amino acid modification 
Out of the 20 natural amino acid residues, chemical modification methods have been 
reported for lysine, cysteine, tyrosine, glutamic acid, aspartic acid, tryptophan, 
histidine and methionine.
24
 Lysine and cysteine, the most nucleophilic residues of the 
naturally occurring amino acids at neutral pH, are the most widely studied and form 
the major targets for protein modification. 
Due to the large natural abundance of lysine, it is often targeted when site selective 
modification is not essential. Over 30 years ago, Fairbanks et al. reported that the 
reaction of lysine with N-hydroxysuccinimide (NHS) esters, at physiological pH and 
in the absence of any exogeneous reagents, forms irreversible amide linkages 
(Scheme 1A).
25
 At higher pH (9-9.5), lysine residues react quantitatively with 
isothiocyanates forming thioureas (Scheme 1B).
26
 Francis et al. reported the use of 
H-benzo[d][1,3]oxazine-2,4-dione to functionalize lysines forming 
orthoaminebenzamide, which can be functionalized further with NaIO4 and dialkyl 
acyl phenylenediamine (Scheme 1C).
27
 Glycoconjugates of bovine serum albumin 
(BSA) have been reported using aldehyde-based reagents to form imines, which can 
be reduced using sodium borohydride to form an irreversible linkage (Scheme 1D).
28
 
Recently, Cal et al. developed a reversible lysine modification based on 
iminoboronates.
29
 These methods demonstrate the wide range of protein modification 
methods available for lysine modification.  
4 
 
Scheme 1. Chemical modifications of lysine 
5 
Methods to functionalize other amino acid residues have also been developed. 
Epoxides react with various nucleophiles leading to random surface modification, but 
have been tuned to react selectively with histidine residues (Scheme 2A).
30
 The 
carboxylic acid groups present on glutamate and aspartate residues, and the C-
terminus can react under peptide coupling conditions using a water soluble 
carbodiimide and HOBt at neutral pH, to form an amide bond,(Scheme 2B).
 31
 A 
highly selective modification of tyrosine has been achieved by a Mannich based 
multi-component reaction under mild conditions at pH 5.5-6.5 (Scheme 2C).
32
 Phenol 
addition to diazonium salts, a widely used reaction in the dye industry, has also been 
used to selectively functionalise the phenol group on tyrosine. Reduction of the azo 
bond by sodium hydrosulfite to aniline allows further functionalisation with a 
substituted acrylamide
27
  and this approach was used to functionalize external surface 
of tobacco mosaic virus capsid.
33
 Preformed imines have also been shown to react 
efficiently with tyrosine.
34
  
 
Scheme 2. Chemical modifications of A) Histidine B) Aspartic acid C) Tyrosine 
1.2.2 Chemical Modifications of Cysteine 
Cysteine is the most nucleophilic residue of the naturally-occurring amino acids and 
has been widely targeted for protein modification. Owing to the low pKa of the thiol 
side chain, cysteines react rapidly with electrophiles, even at low pH. The low 
natural abundance of free cysteine residues make them very attractive targets for site-
selective protein modification.
35
 By introducing cysteine residues at the position of 
6 
interest using site directed mutagenesis,
36
 protein modification can be carried out 
with ease using cysteine reactive reagents.  
1.2.2.1 α-Halocarbonyls 
One of the oldest and most commonly used approaches for cysteine modification is 
through alkylation with α-halocarbonyls (Scheme 3), such as iodoacetamides37 and 
chloroacetamides.
38
 Although α-halocarbonyls suffer from poor chemoselectivity, 
i.e. they often additionally react with lysine residues, they have been used in a wide 
range of applications where a high degree of site-selectivity is not required. For 
example, Brocchini et al. used iodoacetamides to covalently attach flavin to the 
active site of papain, thereby functionally converting a cysteine protease to an 
oxidoreductase.
39
 Flitsch et al. used carbohydrate tethered iodoacetamides to mimic 
asparagine-linked glycoproteins.
40
 Homogeneously glycosylated samples of human 
erthyropoetin
41
 and dihydrofolate reductase
42
 have been accessed using 
iodoacetamide-linked carbohydrates. 
 
Scheme 3. Cysteine labelling with iodoacetamide 
1.2.2.2 Aminoethylation 
Aminoethylation of cysteine was first described over 50 years ago.
43
 The resulting 
moiety acts as a mimic for lysine, with the positive charge being recognised by 
trypsin as a site for proteolytic action (Scheme 4). Methylated lysine analogues 
afforded by this method have been used to study post-translational modifications of 
histones, which control the epigenetic status of cells.
44
 
7 
 
Scheme 4. Cysteine modification by aminoethylation to form A) Lysine mimic 
B) Methylated lysine mimic 
 
1.2.2.3 Michael acceptors 
A reliable way to modify cysteine selectively is via conjugate addition to Michael 
acceptors at neutral pH. A number of α,β-unsaturated systems have been investigated 
and developed as selective cysteine modification reagents. Maleimides
45
 and vinyl 
sulfones
46
 represent traditional reagents for cysteine modification (Scheme 5A). More 
recently, bromomaleimide and related derivatives have been developed that allow 
reversible cysteine modification.
47
 Bromomaleimides react as rapidly as conventional 
maleimides, but revert to free cysteines in the presence of reducing agents such as 2-
mercaptoethanol or TCEP (Scheme 5B).
48
 Novel pyridazinedione-based reagents 
have also been developed. These reagents offer the potential for three points of 
attachment and are completely hydrolytic stable unlike conventional maleimide 
reagents (Scheme 5).
49
  Pyridazinedione-based reagents have also been shown to be 
highly selective for cysteine over lysine and the resultant bioconjugates are reversible 
in an excess of reducing reagent.
53
 
8 
 
Scheme 5.  Cysteine modifications with A) Maleimide B) Bromomaleimide 
C) Pyridazinedione 
1.2.2.4. Disulfides  
Cysteines react rapidly and selectively with disulfides to undergo disulfide exchange, 
with the thermodynamic equilibrium governing the final reaction mixture. 5,5'-
dithiobis-(2-nitrobenzoic acid), often termed as Ellman’s reagent, is widely used to 
measure protein thiol content.
50
 Thiols react stoichiometrically with Ellman’s 
reagent, resulting in the release of 2-nitro-5-thiobenzoate which exists as a dianion in 
alkaline pH. The dianion concentration can then be estimated using a 
spectrophotometer to indirectly measure protein thiol content. More broadly, 
reagents such as methanethiosulfonates allow efficient modification of cysteines to 
form desired disulfides.
51,52
 Synthetic modification of a sulfotyrosine-mimic of P-
selectin-glycoprotein-ligand-1 (PSGL-1),  was carried out using disulfide 
modification of a cysteine using a methanethiosulfonate reagent (Scheme 6). The 
modified protein displayed strong binding to P-selectin and functioned as an 
effective mimic.
53
 Disulfides are versatile covalent linkages, however, they are not 
stable under reducing conditions and revert back to free cysteine. This property has 
been used to great effect in the design of a novel drug delivery approach.
54
  
9 
 
Scheme 6. Methanethiosulfonate modification of cysteine to form tyrosine mimic  
1.2.2.5. Thioethers 
Thioether, unlike disulfide, is a robust linkage that is stable under reducing 
conditions. Davis et al. recently reported the use of tris(dimethylamino)phosphine for 
the conversion of a disulfide linkage to a thioether on a protein.
55
 The conversion of 
a glycosyl-linked cysteine to a thioether under aqueous conditions was also 
reported.
55
 The thioether product was obtained as a mixture of stereoisomers with the 
loss of stereochemistry at the cysteine. This was explained by formation of a 
dehydroalanine intermediate obtained by the β-elimination of thiophosphonium 
intermediate, which underwent conjugate addition of thiol to then form thioether 
(Scheme 7).  
 
Scheme 7. Disulfide to thioether modification 
Under non-aqueous conditions, disulfide substrates without an acidic α-proton have 
been proposed to proceed via the thiophosphonium intermediate.
56 
The reactions 
proceeded with inversion of configuration at the carbon α to the disulfide linkage 
indicating the mechanism to be SN2 (Scheme 8) with the loss of 
hexamethylthiophosphoramide. 
 
Scheme 8. Proposed mechanism of substitution 
10 
Interestingly, Harpp et al. demonstrated conversion of cystine to lanthionine with 
retention of stereochemistry (Scheme 9) in non-aqueous media with a stoichiometric 
amount of tris(dimethylamino)phosphine, indicating that presence of a base is 
essential for formation of dehydroalanine, even for substrates with an acidic  α-
proton.
56
 Desulfurization reactions have also been reported on a number of trisulfide 
substrates.
57,58
 
 
 
Scheme 9. Cystine derivative to lanthionine derivative using 
tris(dimethylamino)phosphine
56 
1.2.2.6. Oxidative elimination of cysteine : Dehydroalanine 
A distinct approach for cysteine modification is represented by the oxidative 
elimination of cysteine to yield dehydroalanine (Dha). Dha is seldom observed in 
nature; rare examples include tyrosine conversion to Dha in thyroglobulin
59
 and the 
conversion of serine to Dha in lantibiotics, such as nisin.
60
 Chemically, Dha is an 
excellent electrophile that undergoes efficient conjugate addition with thiols, and 
thus serves as a versatile handle for protein modification. The reactivity profile of 
Dha allows access to a wide range of protein modifications that mimic some of the 
most prevalent PTMs including phosphorylation,
61
 glycosylation,
62,63
 methylation
64
 
and acetylation.
65
  
11 
 
Scheme 10. Modification of dehydroalanine with thiols 
Lawton et al. reported the first approach to access Dha from cysteine using a double 
alkylation approach; conjugate addition followed by intramolecular annulation 
affording a sulfonium intermediate which undergoes β-elimination to yield Dha.66 
Davis et al. has reported a number of approaches for conversion of cysteine to Dha.
67
 
A single cysteine mutant of subtilisin Bascillus Lentus S156C reacted rapidly with 
O-mesitylenesulfonylhydroxylamine (MSH) to form dehydroalanine under mildly 
basic conditions (Scheme 11).
67
 While MSH also reacts with methionine, the reaction 
is reversible in the presence of DTT.  Unfortunately, MSH is extremely difficult to 
handle, with a number of publications reporting an explosive hazard associated with 
pure and crystalline MSH.
68
 
 
Scheme 11. Conversion of cysteine to dehydroalanine
71
  
12 
Mild and selective bisalkylation approaches that afford efficient conversion of 
cysteine residues to Dha have also been reported. Kajihara et al. reported that diethyl 
meso-2,5-dibromoadipate reacts with cysteine on an 11-residue peptide under mildly 
acidic conditions to give Dha.
69
 A water soluble version of 1,4-diiodobutane (Scheme 
12) is able to affect the conversion of cysteine to Dha on a camelid single domain 
antibody scaffold.
70
 This transformation has been observed in murine and human 
metabolism of anti-cancer drug busulfan and 1,4-dihalobutanes.
71,72,73
 
 
Scheme 12. Conversion of cysteine to dehydroalanine using diiodobutane derivative.  
While Dha modification is a powerful methodology, a significant drawback of this 
approach is the formation of epimeric products. However, this does not necessarily 
preclude its applicability. In a study of acetylated and methylated lysine mimics, 
constructed via a Dha intermediate, both epimers were seen to function as enzyme 
substrates without loss of activity.
74
 
1.2.3 Chemical modification of protein termini 
Terminal protein residues afford additional chemical modes of reactivity that have 
also been exploited to develop site-specific protein modification methods. A number 
of strategies, both chemical and enzymatically catalysed, revolve around the unique 
position and reactivity of terminal amino acid residues and will be discussed in detail 
below.  
1.2.3.1 Native Chemical Ligation 
A number of protein ligation strategies have been developed in recent years.
75
 
Wieland et al. discovered that the reaction of valine-thioester and cysteine led to the 
formation of valine-cysteine dipeptide.
76
 This reaction laid the foundation for the 
development of Native Chemical Ligation (NCL).
77
 NCL is a powerful approach that 
allows for the chemoselective linkage of two peptide or protein fragments. An 
13 
N-terminal cysteine and a C-terminal thioester react to form a native peptide linkage 
under aqueous conditions without the need for any protecting groups (Scheme 13). It 
allows for the installation of protein modifications via the ligation of chemically 
synthesized peptide fragments at the protein termini. Post-translational mimics that 
have been synthesized by chemical modification methods, although analogous, often 
differ chemically from natural post-translational modifications. NCL allows site-
specific installation of native post-translational modifications with retention of 
stereochemistry.  
 
Scheme 13. Native Chemical Ligation (NCL)  
Given the final product contains a cysteine at the ligation position; a major drawback 
of this approach is the low natural abundance of free cysteine residues in native 
proteins. Therefore, to broaden the approach, strategies to convert genetically 
engineered cysteine residue, introduced specifically for NCL, to other naturally 
occurring amino acids have been developed. Dawson et al. reported hydrogenolytic 
desulfurization of cysteine to afford alanine with complete retention of 
stereochemistry to synthesize the first cysteine free peptide using an NCL 
approach.
78
 Danishefsky et al. developed a mild, radical based cysteine-selective 
desulfurization. The reduction is mediated by tris(2-carboxyethyl)phosphine 
(TCEP).
79
  This approach has been used to convert cysteine to both alanine and 
valine (Scheme 14).
80,81
 
 
Scheme 14. NCL at alanine using TCEP mediated desulfurization 
A major advance was achieved in late 90’s with the development of thiol auxiliaries 
(Scheme 15).
82,83,84,85
 These thiol auxiliaries, attached to N-terminus of a synthetic 
14 
peptide, can facilitate ligation and then be removed by using trifluoroacetic acid 
(TFA).  
 
Scheme 15. NCL using removable auxiliary 
It should be appreciated that the chemical synthesis of peptide thioesters is 
challenging and represented another major obstacle to the applicability of this 
approach. To overcome this problem, Muir et al. developed ‘Expressed Protein 
Ligation’ (EPL) as an extension to NCL.86,87,88 This technology utilizes inteins to 
access recombinant polypeptide C-terminal thioesters. Inteins are peptide sequences 
that mediate self-splicing when inserted within a larger precursor polypeptide. They 
are eliminated from the precursor sequence as they facilitate conjugation of the N- 
and C-terminal regions into a new protein. EPL then proceeds through reaction with 
a chemically synthesized or expressed protein or peptide that contains an N-terminal 
cysteine residue. The synthesis of proteins which are very large in size that represent 
a significant challenge with the traditional NCL approach, can thus easily be 
accessed using EPL, e.g. EPL has been used to prepare β’ subunit of Escherichia coli 
RNA polymerase containing 1407 amino acids.
89
 
Though EPL and NCL are very powerful strategies, they both require cysteine 
residues or thiol auxilliaries to affect ligation. Strategies that do not proceed via 
thiol-mediated conjugation have also been developed. One such strategy is 
Staudinger Ligation,
90
 which is essentially an extension of the Staudinger reaction.
91
 
Bertozzi et al. demonstrated that a phosphine can function as an acyl group donor, 
forming an amide bond linkage under aqueous conditions (Scheme 16).
92
 
 
15 
 
Scheme 16. Staudinger Ligation  
Though protein ligation strategies offer a powerful method for the introduction of 
both natural and non-natural protein modifications, there are issues that make this 
approach less amenable than chemical strategies. Synthetic and expressed protein 
and peptide fragments often suffer from poor solubility and large concentrations of 
denaturants are often required to facilitate efficient ligation.
93
 The polypeptides 
formed subsequently require careful re-folding to obtain the desired and correct final 
protein structures.
 94
   
1.2.3.2 Chemical modification of protein termini forming non-native linkages  
N-Terminal residues often exhibit unique chemical properties.  A number of 
chemical and enzymatic methods have been developed to modify the protein N-
terminus with high selectivity.
95,96
  While chemical methods are more general and 
allow for the introduction of a large number of substrates, enzymatic methods are 
more selective but restrictive in the size or type of functional groups that can be 
attached. 
The lower pKa of N-terminal amine residue has been exploited for acetylation by 
careful control of pH, albeit with limited success.
95
 A number of strategies have been 
developed that target specific terminal amino acids. Terminal serine and threonine 
residues react rapidly with periodate under neutral conditions to form an α-N-glyoxyl 
residue which can be functionalized with aldehyde reactive hydrazide reagents to 
allow site-selective functionalisation (Scheme 17).
 97,98
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Scheme 17. Periodate modification of N-terminal serine 
Also, N-terminal tryptophan residues have been shown to react with C-terminal 
aldehyde residues in an acid catalyzed condensation reaction, also known as Pictet 
Spengler reaction (Scheme 18).
99
 
  
Scheme 18. Pictet Spengler condensation of tryptophan 
A more general chemoselective strategy that does not depend on the identity of the 
N-terminal amino acid chain involves oxidation of the N-terminal amino group to an 
imine followed by hydrolysis to afford a ketone or aldehyde.
96
 However, the initial 
conditions that were developed for this reaction were harsh, as the reagents,  
glyoxylic acid, copper(II) salts, pyridine and acetic acid, are unlikely to be tolerated 
by most proteins. However, Francis et al. have reported the same conversion under 
much milder conditions with high selectivity using pyridoxal-5-phosphate (PLP), a 
cofactor that affects a variety of metabolic transformations under enzymatic control, 
including racemization, elimination, decarboxylation, and transamination.
100
Amine 
reacts with the aldehyde component of PLP to afford an imine; the lower pKa of 
N-terminal proton then allows tautomerization to occur uniquely at this site, which, 
following hydrolysis, yields an aldehyde or a ketone. The resultant aldehyde or 
ketone can then be modified further with alkoxyamines to install new functionality 
(Scheme 19).
 100 
17 
 
Scheme 19. PLP mediated N-terminal protein modification  
1.2.3.3. Enzyme-mediated protein termini labelling  
Enzymatic protein labelling methods typically employ an enzyme that selectively 
attaches a chemical probe to the protein terminus with the aid of a recognition 
sequence in an unhindered region of the protein.  Sortase, a transpeptidase found in 
the cell envelope of many Gram-positive bacteria that anchors surface proteins to the 
peptidoglycan cross bridge of the cell wall,
101
 has been exploited for site-selective 
protein labelling. Schneewind et al. reported Staphylococcus aureus sortase (SrtA) 
mediated catalysis of transpeptidation by cleavage between threonine and glycine at 
an LPXTG recognition motif and ligation of the carboxyl group of threonine to the 
amino group of pentaglycine on the cell wall peptidoglycan.
102
 Pollock et al. 
developed a SrtA-mediated protein ligation approach allowing the highly site-
specific labelling of C-terminal protein residues.
103
 Sortase-mediated reactions are 
carried out in calcium containing aqueous buﬀer (pH 7.0-8.5) at nanomolar to 
micromolar concentration of SrtA. However, this approach requires the engineering 
of LPXTG into the protein sequence (Scheme 20). 
 
Scheme 20. Sortase mediated C-terminal labelling 
Turnbull et al. expanded the scope of sortase-mediated protein labelling by 
developing an efficient N-terminal labelling approach.
104
 This approach uses 
18 
depsipeptide substrates for an efficient reaction and proceeds smoothly with 
equimolar quantities of substrates. As with other enzyme-mediated protein 
modification approaches, this method is also restricted by the requirement of a four 
amino acid LPET sequence at the N-terminus of the labelled protein (Scheme 21).   
 
Scheme 21. Sortase-mediated N-terminal protein labelling 
It should also be noted that Ling et al. reported SrtA-mediated synthesis of 
recombinant protein thioesters which are valuable building blocks for protein semi-
synthesis using NCL (Scheme 22).
105
 
 
Scheme 22. Sortase mediated synthesis of C-terminal thioesters for ligation 
 
1.2.4 Insertion of non-natural amino acids 
Despite the advances in chemical modification of natural amino acids, multiple 
copies of canonical amino acid residues in native protein structures can make the 
site-selective modification of proteins challenging. Chemical modifications of 
naturally occurring amino acid residues are often based on nucleophilicity, and 
selectivity delivered via careful control of pH and substrate stoichiometry. A 
fundamentally different approach for protein modification involves the 
genetically-controlled insertion of unnatural amino acid residues into a protein 
sequence. These unnatural amino acids are typically designed to present 
bioorthogonal side-chain functionality, hence allowing the potential for exquisite 
site-selective and efficient protein modification.  
1.2.4.1. Use of auxotrophic strains 
The most straightforward method to incorporate non-natural amino acids into 
recombinant proteins is to use auxotrophic strains of E. coli. These strains are unable 
19 
to synthesize a specific canonical amino acid and rely on uptake from the growth 
media. In this growth media, the specific amino acid can be replaced by a structurally 
similar analogue. The structurally similar analogue is then incorporated by the 
bacteria. This approach requires careful inducible control, as the cells are first grown 
in normal media and then transferred to another media containing the non-natural 
amino acid. Following induction, proteins with this non-natural amino acid 
incorporated are expressed.    
Methionine, one of the rarest naturally occurring amino acid residues, is an excellent 
target for non-natural amino acid incorporation. Methionine has been successfully 
replaced with alkyne and azide analogues (Figure 2)
106,107,108
 that allow for 
subsequent protein modification with a copper-catalysed, Huisgen cycloaddition 
reaction (Scheme 23).
109,110
 
 
Scheme 23. A. Huisgen reaction on azidophenylalanine  
 
Figure 2. Methionine analogues successfully incorporated in E. coli 
This approach has also been extended to label proteins in vivo.
108
 Apart from 
methionine, other amino acids such as leucine,
111
 isoleucine,
112
 phenylalanine,
113
 
proline,
114
 and tryptophan
115
  have been replaced by non-natural amino acids using 
this strategy. This method allows for the ability to replace all copies of an existing 
canonical amino acid with a non-natural amino acid analogue. However, it does not 
allow expansion of the genetic code or incorporation of additional non-natural amino 
acids into the protein. 
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1.2.4.2. Stop codon suppressor tRNA 
Noren et al. developed an even more powerful method to expand the existing set of 
amino acids by translationally incorporating non-natural amino acids into proteins by 
expanding the genetic code. This was accomplished by ‘hijacking’ the amber stop 
codon (UAG) to encode for the non-natural amino acid.
116
 A stop codon is a 
nucleotide triplet in mRNA that usually signals the termination of translation. 
tRNAs found in yeast efficiently recognise this amber stop codon (UAG), and 
prevent the release factor from binding to this codon. The ribosome therefore reads 
through the stop codon and continues protein translation. The other important 
components in the process of protein elongation, peptidyltransferase and elongation 
factor, show broad specificity.
23
 Incorporation of an additional non-natural amino 
acid is achieved by aminoacylating the amber codon suppressor tRNA with the non-
natural amino of choice (Figure 3). 
 
Figure 3. Amber codon suppressor method for incorporation of non-natural amino 
acids (figure reproduced from Graff et al.) 
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One significant drawback of this approach is that the aminoacylated tRNAs are too 
large to be taken up by the cell. Aminoacylated tRNAs therefore need to be 
microinjected into the host cell, and large cells such as Xenopus Oocytes
117
  have 
been used for this purpose. It should be noted that proteins have also been 
successfully expressed in a cell free system.
118
 However, while the overall method is 
very powerful, it presents significant technical challenges, especially for large scale 
expression, and therefore does not constitute a widespread general protein 
modification method.  
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1.2.4.3. Orthogonal aminoacyl-tRNA synthetase 
To overcome the problem of microinjection, suppressor tRNA and the corresponding 
aminoacyl-tRNA synthetase can be produced from the host cell itself by genetic 
engineering.
119
 This new pair must be orthogonal to host tRNA/tRNA-synthetase 
pairs: the introduced tRNA should not be a substrate for any host aminoacyl-tRNA 
synthetase and must function efficiently, while the introduced aminoacyl-tRNA 
synthetase must not aminoacylate any host tRNAs and should be selective for the 
introduced tRNA.
120
 This requirement of orthogonality is met by using tRNA-tRNA 
synthetase pairs from other organisms, provided the cross species aminoacylation is 
inefficient.
121,122
 
The non-natural amino acid to be aminoacylated, and subsequently introduced in the 
protein sequence, must be available in the protein cytoplasm. The non-natural amino 
acid must therefore be designed to be transported into the cytoplasm, and is added 
exogenously in the growth media to facilitate this process. Schultz et al. reported the 
biosynthesis of non-natural amino acid in situ by modifying the biochemical 
pathways of E. coli. This amino acid was then incorporated by an orthogonal tRNA-
aminoacyl tRNA synthetase pair, eliminating the need for non-natural amino acids to 
be added externally (Scheme 24).
123
 
 
Scheme 24. Biosynthesis of non-canonical aminoacid in E. coli using series of 
phosphatidate phosphatase enzymes 
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Rapid advances are currently being made in this field, with novel genetic approaches 
including the development of an orthogonal ribosome-mRNA pair 
124
 and the advent 
of four base codons,
125
 which pave the way for improved efficiency. Despite these 
advances, however, a number of challenges remain. This approach often suffers from 
low efficiency and poor yield for two reasons: i) the aminoacylation efficiency of 
these newly derived tRNA synthetases is often limited and ii) there is a significant 
competition between the release factor and the suppressor tRNA for the amber 
codon.
126
 Consequently, incorporation of multiple non-natural amino acids is often 
difficult as the efficiency decreases multiplicatively with the increase in the number 
of amber codons in a gene. Another problem associated with this approach is that the 
fidelity of incorporation of non-natural amino acids varies from system to system, 
and often with poor reproducibility. Practical challenges also exist, for example, 
growth media must be supplemented with the non-natural amino acid, often leading 
to a high cost of expression. Finally, the protein expression system remains 
technically challenging for most standard biochemistry laboratories and hence the 
approach remains restricted to specialist laboratories. 
1.3  Dual modification of proteins 
While a large array of methods are available for site-selective single protein 
modification, the site-selective dual-labelling of proteins has remained a challenge. 
Certain applications require that two functional groups be introduced into a protein in  
site-specific manner. Examples where the site-selective, dual-modification of 
proteins is desired include Förster resonance energy transfer (FRET)
127
 experiments 
for  folding studies,
128
  targeted theranostic biopharmaceuticals using viral 
capsids
129,130
 and protein-drug therapeutics that are stabilised with conjugated half-
life extension chemistry e.g. poly(ethyleneglycol) (PEG).
131
 Cysteine is often the 
preferred target for the first modification, but a second site for chemoselective 
functionalization may not always be available. Early methods have tried to exploit 
differences in cysteine accessiblity to achieve site-specific, dual-cysteine labelling 
using reagent control. However, it is difficult to achieve homogeneous labelling 
using this approach.
132,133,134,135
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1.3.1 Dual labelling through functionalisation of C- and 
N-terminus 
Site-selective N- and C-terminal labelling methods exploit the unique reactivity of 
terminal residues to introduce dual functionality. As described earlier, methods that 
facilitate the sortase-mediated labelling of terminal amino acid reisudes have been 
developed. Ploegh et al. developed a strategy for introducing different chemical 
labels at the terminii of a protein using different sortase enzymes, SrtAstrep and 
SrtAstaph.
136
 A fluorophore-labelled Ala-Ala conjugate served as the nucleophile for 
the first SrtAstrep-mediated protein ligation. Thrombin cleavage was then used to 
expose a masked glycine residue for a second SrtAstaph-mediated ligation to another 
fluorophore conjugated with the required amino acid recognition sequence (Scheme 
25). 
 
Scheme 25. Dual labelling of proteins 
Wu et al. developed two chemoselective reactions for a one-pot protein dual 
labelling of Rab7D3 for protein folding studies.
137
 C-Terminal labelling was 
accomplished by oxime ligation followed by NCL modification of an N-terminal 
cysteine. Intein-mediated formation of a C-terminal thioester protein was followed 
by reaction with a (bis)oxyamine moiety, which was subsequently modified with a 
keto fluorophore under mild conditions.
138
 An N-terminal cysteine was then exposed 
by TEV protease cleavage, and chemoselectively-functionalized using NCL to attach 
another fluorophore for FRET studies.  
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Scheme 26. One pot dual labelling of proteins for single molecule FRET analysis 
Single molecule FRET often requires that fluorophores be placed on a specific part 
of a protein that undergoes dynamic conformational changes. Santoso et al. studied 
the fingers-closing conformational transitions of DNA Polymerase I by placing one 
fluorophore on a mobile segment of the fingers subdomain (residue 744) and a 
complementary fluorophore at the base of the thumb subdomain (residue 550), 
enabling measurement of the inter-fluorophore distance change upon 
fingers-closing.
139 
 
Figure 4. A. FRET studies of DNA Polymerase – I139 B. MS2 virus capsid for drug 
delivery (figure reproducted from Francis et. al.)
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1.3.2 Labelling protein fragments 
The second approach for site specific dual labelling proteins relies on generating 
protein fragments, and labelling the fragments individually often via cysteine 
modification, and joining the proteins together through ligation methods.
141,142
 This 
facilitates non-terminal, dual-modification of proteins.  
25 
Rosa et al. developed a homogeneous dual-labelling strategy, using an EPL 
approach, and used it to dual-label CTPR3 (Consensus TetratricoPeptide Repeat) 
with two fluorophores at specific positions in the protein.
142
 By using EPL to express 
either an N-terminal protein fragment or full protein, both as C-terminal thioesters, 
Rosa was able to differentially position the two fluorophore labels (Scheme 27).  
 
Scheme 27. Dual labelling of proteins using NCL A) Labelling of protein fragments 
B) Single labelling of protein followed by Cysteine labelling at C-terminus 
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Yang et al. reported an alternative approach to cysteine labelling of fragments to 
afford a dual-labelled diUbiquitin structure, thus facilitating FRET studies.
141
 The 
approach relied upon generating protein fragments that contained a single cysteine 
for fluorophore conjugation, labelling each individual cysteine, and joining the 
fragments to generate a full-length protein through split intein-mediated protein 
splicing (Scheme 28).
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Scheme 28. Dual labelling via split inteins (figure reproduced from Yang et al.) 
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Expressing proteins as fragments and labelling the individual fragments to achieve 
dual-labelling allows homogeneous functionalisation at non-terminal positions. The 
biggest limitation of this approach is represented by the stability of protein-expressed 
fragments. These fragments are often insoluble, representing a significant synthetic 
challenge.
93
 Finally, this approach requires a large number of steps and often harsh 
conditions to achieve homogeneous dual labelling, which may not be amenable for 
proteins which exhibit poor stability and/or sensitive functional groups.
94
  
1.3.3 Using non-natural amino acids 
A further approach that facilitates homogeneous dual labelling is the introduction of 
non-natural amino acids, often in conjunction with a traditional site selective method, 
e.g. cysteine modification. The ways of introducing a non-natural amino acid have 
been discussed in Section  1.2.4.  
Pluckthun et al. reported a facile dual labelling approach for Designed Ankyrin 
Repeat Proteins (DARPins) using a combination of non-natural amino acid and 
cysteine functionalisation.
144
 Azidohomoalanine was introduced, at the N-terminus 
as an analogue of the initiator methionine using auxotroph techniques. Additionally, 
a cysteine was introduced at a second position of interest via site-directed 
mutagenesis. Strain-promoted azide-alkyne cycloaddition chemistry was utilized for 
27 
orthogonal functionalisation of azidohomoalanine, followed by maleimide 
modification of the single cysteine residue to obtain homogeneous dual 
functionalized DARPin (Figure 5).
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Figure 5. DARPin dual functionalisation using ‘click’ reaction and thiol 
modification 
Chin et al. has reported the incorporation of two non-natural amino acids into a 
protein by synthetically evolving an orthogonal ribosome that efficiently decodes a 
series of quadruplet codons and the amber codon, providing several blank codons on 
an orthogonal mRNA, which it specifically translates. They created mutually 
orthogonal aminoacyl-tRNA synthetase–tRNA pairs and combined them with ribo-
Q1 to affect incorporation of two non-natural amino acids into the protein 
sequence.
146
 At the same time, Liu et al. independently developed another method to 
introduce two non-natural amino acids in the same protein by using two stop codons, 
amber codon UAG and ochre codon UAA.
147
 This method was used to incorporate 
two fluorophores for FRET analysis of glutamate binding protein (QBP) and 
superfolder green fluorescent protein (GFP).  
In summary, a range of techniques for protein bioconjugation have been developed 
over the years for a variety of applications. Each of these techniques has associated 
advantages and disadvantages. There is undoubtedly a clear need for development of 
novel bioconjugation methods that facilitate greater homogeneity and site selectivity 
for single and multiple protein modification with simplicity and efficiency. The 
development of such methods is certain to allow a better understanding of biological 
processes and development of improved therapeutics, diagnostics, imaging and 
related applications.  
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1.4 Aims 
The following thesis aims were identified: 
1. Site-selective dual labelling of proteins 
Many approaches that facilitate the site-selective, dual-labelling of proteins suffer 
from a number of drawbacks. Modification of protein termini for dual labelling 
allows chemical probes to be placed only on N- and C-termini. Fragment based dual 
labelling methods suffer from poor solubility and stability of protein fragments. 
Approaches that introduce non-natural amino acids are technically restrictive for 
most biochemistry and chemical biology laboratories, require access to uncommon 
bacterial strains, the expression yields are often poor and they are expensive to 
perform. Thus, there is a serious lack of an accessible and general site-selective, dual 
modification approach. A simple, robust and effective dual-modification approach 
was envisaged via the different chemical modification of two cysteines selectively in 
a single protein. The potential for obtaining differential reaction modes on similarly 
accessible cysteine residues, using protein tertiary structure to control reaction 
outcome (substrate control), was to be investigated with a view of developing a 
general site-specific, dual-labelling strategy (Scheme 29).  
 
Scheme 29. Proposed site-specific dual labelling of cysteine residue via substrate 
control 
2. Chemical methods for mimicking post-translation modifications (PTMs) 
Despite recent progress in the development of techniques for accessing post-
translationally modified proteins and their analogues, there remains scope for 
development of improved chemical modification methods. One powerful method to 
access PTMs is via dehydroalanine.
6,9
  However, products derived from the 
conjugate addition of a nucleophile onto Dha are likely to be a mixture of 
29 
stereoisomers, due to loss of stereochemical information (Section  1.2.2).
155 
Cysteine 
activation via thiophosphonium and subsequent nucleophilic displacement of the 
thiophosphonium adducts
56
 was investigated as a potential method for accessing 
PTM analogues without loss of native stereochemistry. 
 
Scheme 30. Proposed route for accessing PTM analogues 
3. Reversible cysteine modification using bromomaleimides. 
Novel bromomaleimide reagents have been developed within the Caddick and Baker 
groups at UCL, to enable the reversible modification of cysteine. These 
bromomaleimides react rapidly and selectively with cysteine residues on proteins and 
peptides to afford thiomaleimides, which can be converted back to free thiols in the 
presence of excess reducing agents such as tris(2-carboxyethyl)phosphine (TCEP)  
and 2-mercaptoethanol. This chemistry has considerable potential, particularly in the 
development of reagents that will facilitate the reversible affinity capture of proteins. 
The current necessity for a large excess of reducing agent to facilitate cleavage of 
bromomaleimide-bioconjugates could be detrimental to the structural stability of 
modified proteins, and therefore poses a challenge to the general applicability of the 
thiomaleimide reversibility approach. The development of an alternative, efficient 
and selective cleavage strategy, which would represent a significant advantage over 
the existing strategy, was explored (Scheme 31).  
 
Scheme 31. Development of efficient cleavage strategy for reversible cysteine 
modification 
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Chapter 2 Site-selective homogeneous 
dual labelling of proteins 
2.1 Introduction 
Site-selective protein labelling is widely achieved by reaction of a genetically 
engineered cysteine residue at a specific position in the protein of interest, with an 
appropriate label (Section  1.2.2).
148
 Site-selective dual labelling of proteins 
represents a significant challenge due to the lack of reactive, orthogonal, non-
abundant natural amino acid residues. Previous methods for site-selective dual 
modification have relied on introducing the second label by targeting terminal 
residues, introducing unnatural amino acids or labelling protein fragments 
(see Section  1.3).  
Most protein modification methods designed for natural amino acids 
(see Section  1.2.1) rely on the nucleophilicity of the target residue. Selectivity is 
achieved almost exclusively by using protein modification reagents carefully 
designed to exploit the differences in reactivity of the amino acid side chains under 
carefully controlled conditions, for example under physiological conditions, 
N-hydroxysuccinimide esters react selectively with lysines
25
 whilst maleimides react 
almost exclusively with cysteines.
45
 
Cysteine modification is the most widely used approach for site-selective 
homogenous protein labelling (see Section  1.2.2). One cysteine modification of 
particular interest proceeds via the oxidative elimination of cysteine to 
dehydroalanine. This method can be broadly described in two steps: Step 1 involves 
the reaction of the cysteine 1 with an activating reagent to form intermediate 2; Step 
2 involves elimination to form dehydroalanine 3 (Scheme 32). Dehydroalanine can 
then be modified with a variety of thiol nucleophiles to introduce the desired protein 
modification. 
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Scheme 32. Conversion of cysteine to dehydroalanine 
Lawton et al. first reported a convenient method for converting cysteine into a 
suitably activated intermediate via the bisalkylation of cysteine.
66
 N-Acetylcysteine 4 
underwent a conjugate addition reaction with quinonediimide derivative 5 to form 6. 
This species then underwent intramolecular annulation to form an activated 
sulfonium intermediate 7 which eliminated a sulfide to afford dehydroalanine 8 
(Scheme 33).  
 
Scheme 33. Conversion of cysteine 4 to dehydroalanine 8 using quinonediimide 
derivative 5 
Kajihara et al.
 
subsequently reported the reaction of diethyl meso-2,5-
dibromoadipate 10 with a cysteine on a 10-residue peptide 9.
69 
The free thiol of the 
cysteine residue underwent a nucleophilic displacement reaction with 10 to initially 
form thioether 11. This was followed by an intramolecular nucleophilic displacement 
32 
reaction to form an activated sulfonium intermediate 12, which underwent rapid 
elimination to form dehydroalanine 13 (Scheme 34). 
 
Scheme 34. Conversion of cysteine 9 to dehydroalanine 13 on a peptide using 
meso-2,5-dibromoadipate 10 
Davis et al. reported conversion of cysteine to dehydroalanine on proteins using 2,5-
dibromohexanediamide 14.
70
 A cysteine mutant of a single domain camel antibody 
(A104C) 15 and a cysteine mutant of subtilisin SBL (S156C) 18 underwent reaction 
with 2,5-dibromohexanediamide 14 to form dehydroalanine derivatives 16 and 19 
(pH 8, 37 °C) (Scheme 35A and Scheme 35B). The reaction pathway was observed to 
be analogous - after the formation of thioether 22, the reaction is thought to proceed 
via an activated sulfonium intermediate 23 that undergoes rapid elimination to 
dehydroalanine 24 (Scheme 35C). 
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Scheme 35. Reaction of 2,5-dibromohexanediamide 14 with A) Single cysteine 
mutant of single domain camel antibody 15 B) Single cysteine mutant of subtilisin 18        
C) Cysteine derivative 21 
2.2 Aims  
Chemical methods for protein modification rely primarily on reagent control for 
selective protein labelling. However, protein modification reactions in vivo are 
typically substrate-controlled.
8 
The desired modification is usually catalysed by an 
enzyme that recognises an amino acid sequence or element of tertiary structure on 
the target protein. It would therefore be of interest to know whether substrate control 
can be used to effect chemical protein modification and, in particular, whether it can 
34 
be used to differentiate the reactivity of two cysteine residues on a protein surface to 
facilitate the homogeneous, dual modification of a protein.  
Oxidative elimination of cysteine to dehydroalanine is one approach that is likely to 
be amenable to such substrate control. The transformation of cysteine to 
dehydroalanine via bisalkylation can be broadly classified into three steps (Scheme 
36).  
1. Alkylation of cysteine 25 to form thioether 26; 
2. Conversion of thioether 26 to sulfonium 27;  
3. β - Elimination to sulfonium 27 to form dehydroalanine 28.  
 
Scheme 36. Modification of cysteine 25 to dehydroalanine 28 via bisalkylation 
Whilst step 1 of the reaction sequence (Scheme 36) is likely to be reagent controlled, 
steps 2 and 3 may dependent on the tertiary structure of the protein, e.g., steric 
factors may prevent formation of sulfonium at certain positions on the protein (step 
2). Similarly, a solvent inaccessible α-proton in a highly structured region of a 
protein could prevent elimination of the sulfonium intermediate (step 3). It may, 
therefore, be possible to use ‘substrate-control’ to obtain different reaction outcomes 
for similarly accessible cysteine residues by controlling the parameters essential for 
steps 2 and/or 3 of the reaction.  
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To probe this theory, the following aims were identified: 
1. Identify an appropriate protein model system and design cysteine mutants in 
different regions of protein tertiary structure; 
2. Identify an appropriate reagent for bisalkylation of cysteine and investigate 
the reaction outcomes on the model protein to obtain evidence of substrate-
controlled protein modification; 
3. Design a strategy to exploit differential cysteine reactivity for the dual-
modification of proteins; and 
4. Demonstrate the utility of this substrate-controlled homogeneous dual 
labelling strategy. 
2.3 Model System 
Superfolder green fluorescent protein (GFP, PDB ID: 2B3P) 29, was chosen as a 
model protein to explore bisalkylation of cysteine for substrate controlled chemical 
modification. Superfolder GFP has a β-barrel structure, displays excellent stability at 
elevated temperatures and has found wide-ranging applications especially in 
imaging.
149
 It also contains two native cysteine residues, Cys-48 and Cys-70, both of 
which have been reported to be inaccessible for chemical modifications (Figure 
6).
149
  
 
Figure 6. Superfolder Green Fluorescent Protein (Cys48, Cys70) 
Cys 48 
Cys 70 
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To explore different reaction outcomes following cysteine bisalkylation, three single 
cysteine GFP mutants (+CG 30, T230C 31, S147C 32) were designed, cloned and 
expressed (Figure 7) (GFP (T230C) 31 and GFP (S147C) 32 were expressed by Paul 
Moody, PhD student, Caddick Group). Superfolder GFP 29, in absence of any 
reactive cysteine residue was expressed as a control for the reactions. GFP (+CG) 30 
was designed with a cysteine residue close to C-terminal end of GFP in a highly 
flexible region away from the β-barrel. This residue was introduced in a region with 
no bulky amino acid side chains or tertiary structure likely to inhibit the formation of 
the sulfonium intermediate (step 2, see Scheme 36). Moreover, the α-proton for this 
residue was likely to be highly solvent accessible, and hence the sulfonium 
intermediate is likely to undergo rapidly elimination to dehydroalanine (step 3, see 
Scheme 36). This residue was designed to have a similar reaction mode to the 
examples described in the literature namely SBL (S156C), Histone (K9C),
74
 and the 
camel antibody (A104C).
70,74
  
GFP (T230C, 233Δ) 31 was designed with a cysteine residue closer to the β-barrel 
with a solvent accessible -proton of residue 230 (solvent accessible surface area = 
4.3 Å
2
).
150
 Residues around the position 230 could sterically inhibit cyclisation to the 
sulfonium (step 2, see Scheme 36) but the high α-proton accessibility was expected to 
facilitate elimination to dehydroalanine (step 3, see Scheme 36) (Figure 7).  
GFP (S147C) 32 was designed with a cysteine residue close to the highly structured 
protein -barrel to shield the -proton of S147, thus rendering it inaccessible 
(solvent accessible surface area = 0.0 Å
2
),
150
 This was hypothesized to prevent rapid 
elimination of sulfonium to dehydroalanine (Step 3, see Scheme 36) (Figure 7). 
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Figure 7. A) GFP mutants with cysteine residues in different environments 
B) α-proton accessibility (α-proton coloured and circled in red)  
  
2.4 Reaction with N-methylmaleimide 
The reactivity and the accessibility of the cysteine residues of all four GFP variants 
29, 30, 31 and 32 was determined by treatment with N-methylmaleimide as a 
standard cysteine reactive reagent. As protein structure was unexpected to play any 
role in the outcome of reaction of GFP single cysteine mutants with 
N-methylmaleimide, the reaction was expected to be ‘reagent-controlled’ and hence 
identical reaction products were expected. 
The GFP variants were subjected to a 20-fold excess of N-methylmaleimide at room 
temperature under mildly basic conditions (sodium phosphate buffer, 100 mM, pH 8) 
and analysed by LCMS after 1 h. GFP (superfolder) 29 served as a control and 
yielded no reaction with N-methylmaleimide, confirming the absence of maleimide 
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reactive residues at this concentration of maleimide relative to the protein (Scheme 
37). 
 
Scheme 37. Reaction of GFP 29 with N-methylmaleimide 
GFP mutants GFP (+CG) 30, GFP (T230C, 233Δ) 31 and GFP (S147C) 32 reacted 
smoothly and rapidly with N-methylmaleimide, giving complete reaction with 
cysteine residues forming the expected reaction products (Scheme 38). 
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Scheme 38. Reaction of GFP 30, 31 and 32 with N-methylmaleimide 
These reactions indicated that the three cysteine mutants behaved in an identical 
manner when subjected to ‘reagent-controlled’ modification. It can be concluded that 
reaction outcomes of these single cysteine mutants were likely to be identical with 
other ‘reagent-controlled’ cysteine modification approaches (see Section  1.2.2). 
2.5 Reactions with 2,5-dibromohexanediamide  
Reaction of the single cysteine mutants of GFP with a sulfonium-forming reagent 
was then appraised. The reagent, 2,5-dibromohexanediamide 14, previously reported 
for the conversion of cysteine to dehydroalanine on a number of proteins under mild 
conditions,
70,74
 was chosen as the model reagent for investigating the reaction of 
cysteine with a sulfonium forming reagent. The reagent was synthesized from adipic 
acid as described in the literature in a 40% yield (Scheme 39). 
40 
 
 
Scheme 39. Synthesis of 2,5-dibromohexanediamide 14 
Prior to reacting 2,5-dibromohexanediamide 14 with any of the mutants, the GFP 
mutants were treated with dithiothreitol (DTT) to reduce any disulfide that may lead 
to incomplete reactivity. Excess reducing agent was removed by repeated 
diafiltration into fresh buffer (sodium phosphate, 100 mM, pH 8). Due to the poor 
solubility of 2,5-dibromohexanediamide 14 in water, the reagent was added as a 
DMF solution to give a final 10% DMF concentration in the reaction mixture.  
To ensure that DMF did not affect the protein or the reaction, the GFP mutants were 
incubated in buffer (sodium phosphate, 100 mM, pH 8) containing 10% DMF for 2 h 
at 37 °C in the absence of any reagent. LCMS analysis indicated that the proteins 
were stable after 2 h at 37 °C.  
Reactions previously reported in the literature on single cysteine protein mutants 
with 2,5-dibromohexanediamide 14 were carried out under mildly basic conditions 
(sodium phosphate buffer, 100 mM, pH 8) with a large excess of the reagent (1500 
equivalents) at 37 °C. Therefore, similar conditions were employed for reaction of 
2,5-dibromohexanediamide 14 with each of the four GFP variants (29,30,31 and 32) 
to ensure the consistency and comparability of the data with that reported in the 
literature. As expected in the absence of accessible cysteine residues, incubation of 
superfolder GFP 29 with 2,5-dibromohexanediamide 14 (1500 equivalents, 2 h, 
37 °C) showed no reaction by LCMS (Scheme 40). 
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Scheme 40. Reaction of superfolder GFP 29 with 2,5-dibromohexanediamide 14 
Reaction of single cysteine GFP mutants (30, 31, 32) with 
2,5-dibromohexanediamide 14 provided interesting results. GFP (+CG) 30 reacted 
smoothly with 14 (1500 equivalents, 2 h, 37 °C) to give clean conversion to GFP 
(+CG, Dha) 39. This was the expected outcome as the cysteine residue is in a highly 
flexible region of the protein with no crystal structure available, hence the α-proton 
was likely to be accessible (Scheme 41). The cysteine residue at position 230 on 31, 
closer to β-barrel fold of GFP, also underwent a similar reaction to yield GFP 
(T230C, 233Δ, Dha) 40 in complete conversion (Scheme 41).  
 
Scheme 41. Reaction of GFP (+CG) 30 and GFP (T230C, 233Δ) 31 with 2,5- 
dibromohexanediamide 14 
On the other hand, GFP (S147C) 32, under the same reaction conditions, did not 
yield GFP (S147C, Dha) 41. Instead, LCMS indicated quantitative conversion to 
42 
GFP (S147C, Sulf) 42 (Scheme 42).  The isolation of this sulfonium species as a 
stable adduct was noteworthy as this intermediate had not previously been isolated. 
Crucially, the lack of formation of any GFP (S147C, Dha) 41 indicated a level of 
substrate control in the outcome of the reaction of a cysteine residue with 2,5-
dibromohexanediamide 14. 
 
Scheme 42. GFP(S147C) 32 reaction with 2,5 dibromohexanediamide 14 
In order to gain further evidence for the site of reaction between GFP (S147C) 32 
and 2,5-dibromohexanediamide 14, GFP (S147C, Sulf) 42 was treated with 
N-methylmaleimide (20 eq). No reaction was observed, confirming that cysteine 147 
had been modified.  
 
Scheme 43. Reaction of GFP (S147C, Sulf) 42 with N-methylmaleimide 
Efforts were made to optimize the reaction conditions for the formation of sulfonium 
42 by varying reaction parameters, including number of equivalents of 
43 
2,5-dibromohexanediamide 14, reaction temperature, and reaction time (Table 1). 
The yield of GFP (S147C, Sulf) 42 under different reaction conditions was estimated 
by ratio of peak heights in the deconvoluted mass spectra.
74
  
At 21 °C, no sulfonium 42 was detected after incubation of GFP (S147C) 32 with 10 
equivalents of 2,5-dibromohexanediamide 14 for 2 h (Table 1, Entry 1). After 
prolonged incubation for 20 h, sulfonium 42 was formed in 53% yield (Table 1, 
Entry 3). Increasing the equivalents of 2,5-dibromohexanediamide 14 to 25 followed 
by incubation for 5 h led to the formation of a mixture of sulfonium 42 and thioether 
43 with only 50% conversion being observed (Table 1, Entry 3). Encouragingly, 
sulfonium 42 was observed in complete conversion after the incubation of GFP 
(S147C) 32 with 2,5-dibromohexanediamide 14 for 20 h (Table 1, Entry 6). 
Increasing the equivalents of 2,5-dibromohexanediamide 14 to 50, followed by 
incubation for 20 h also led to complete conversion to sulfonium 42, and no other 
side reactions were detected by LCMS (Table 1, Entry 9). 
On ice, the reactions proceeded very slowly. After 20 h, no reaction of GFP (S147C) 
32 was observed with 10 equivalents of 2,5-dibromohexanediamide 14 (Table 1, 
Entry 10). Increasing the equivalents of 2,5-dibromohexanediamide 14 to 25 led to 
formation thioether 43 as the sole product in only 20%  yield (Table 1, Entry 11). 
Reaction with 50 equivalents of 2,5-dibromohexandiamide 14 after 20 h yielded 
sulfonium 37 in only 20% yield, with 56% of GFP (S147C) 32 being unreacted 
(Table 1, Entry 12).  
At 37 °C, treatment of GFP (S147C) 32 with only 50 equivalents of 
2,5-dibromohexanediamide 14 yielded sulfonium 42 after 2 h (Table 1, Entry 13) .  
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Entry 
 
14 
eq 
 
 
Temp 
(°C) 
 
Time 
(h) 
 
32 
(%)
[a]
 
 
43 
(%)
[a]
 
 
42 
(%)
[a]
 
1 10 21 02 >95 00 000 
2   05 091 09 000 
3   20 047 00 053 
4 25 21 02 081 19 000 
5   05 050 17 033 
6   20 000 00 >95 
7 50 21 02 056 23 021 
8   05 027 25 048 
9   20 000 00 >95 
10 10 04 20 >95 00 000 
11 25  20 080 20 000 
12 50  20 056 24 020 
13 50 37 02 000 00 >95 
 [a] Determined by ratio of peak heights in deconvoluted mass spectrum. 
Table 1. Optimization of formation of GFP (S147C, Sulf) 42 
2.6 Sulfonium stability 
The stability of the sulfonium species was evaluated by incubation of 
GFP (S147C, Sulf) 42 at 37 °C in buffer (sodium phosphate, 100 mM, pH 8) for a 
prolonged period of time. Even after 24 h, no GFP (S147C, Dha) 41 was observed. 
Instead, 45% of the construct degraded to an unidentifiable product. The mass of this 
degradation product was lower than GFP (S147C, Sulf) 42, but higher than GFP 
(S147C) 28. No degradation fragments with mass lower than GFP (S147C) 32 were 
observed. 
45 
At lower temperatures, GFP (S147C, Sulf) 42 appeared to be very stable. No 
degradation was observed after storing the sample at 4 °C in buffer (sodium 
phosphate, 100 mM, pH 8) for up to 1 month. 
2.7 Reactivity of dehydroalanine and sulfonium 
The utility of the dehydroalanine functionality has been amply demonstrated by its 
ability to react with thiol nucleophiles in a facile manner and has been widely 
reported in the literature.
67 
The robustness of dehydroalanine mediated 
functionalisation has been demonstrated using a broad range of thiol nucleophiles 
including thiophosphate, thioglucose and cysteamine derivatives for synthesis of 
post-translationally modified protein mimics (Scheme 44). 
 
Scheme 44. Functionalisation of SBL156Dha 19 to methylated lysine mimic 44 and 
phosphorylated serine mimic 45 
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The utility of sulfonium modification is dependent on its ability to serve as a handle 
for further protein functionalisation. To investigate if sulfonium species could also 
offer broad thiol reactivity as observed with dehydroalanine, GFP (S147C, Sulf) 42 
was evaluated with model thiol nucleophile, 2-mercaptoethanol (1000 eq., 37 °C, 2.5 
h). Gratifyingly, a clean conversion to thioether 46, presumably via ring opening of 
the sulfonium 42 was observed by LCMS (Scheme 45).  
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Scheme 45. Reaction of GFP (S147C, Sulf) 42 with 2-mercaptoethanol 
To evaluate the reactivity of sulfonium moiety further, GFP (S147C, Sulf) 42 was 
treated with a number of different thiol nucleophiles. The reactions were carried out 
whilst varying time, temperature and equivalents of nucleophile. At 21 °C, GFP 
(S147C, Sulf) 37 incubated with a sodium salt of 1-thio-β-D-glucose (100 eq., 
sodium phosphate buffer, 100mM, pH 8) afforded GFP thioglucose conjugate 47 as 
the sole product, with complete conversion after 5 h (Table 2, Entry 2). Reaction of 
GFP (S147C, Sulf) 42 with glutathione under similar conditions also successfully led 
to formation of glutathione conjugate 48 (Table 2, Entry 4).   
These reactions could also be carried out effectively with fewer equivalents (10 eq.) 
of 1-thio-β-D-glucose and glutathione at a higher temperature (37 °C), affording the 
expected products in with complete conversion after 5 h (Table 2, Entries 1 and 3). 
Reaction time could be effectively reduced by increasing the concentration of thiol 
nucleophile (Table 2, Entry 4). Encouragingly, the sulfonium functional group 
proved to be a versatile and reactive intermediate that tolerated functionalisation with 
a range of thiol nucleophiles. Thus, sulfonium modification represents a 
complementary approach for cysteine modification through dehydroalanine for 
cysteine residues which do not undergo elimination.  
The reactivity of the sulfonium was due to the polarization of C-S
+
 bond and the 
strain of the 5 membered ring system, hence it was expected to be significantly 
different from dehydroalanine. The reactivity of GFP (S147C, Sulf) 42 towards non 
sulfur containing nucleophiles was thus investigated. 
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Entry Nuc 0          eq. Temp 
(°C) 
Time 
(h) 
Yield 
%
 [a]
 
Prod. 
       
   
1 
 
0010 37 5 >95 47 
2 0100 21 5 >95  
3 
 
0010 37 5 >95 48 
4 0100 21 5 >95  
5 0200 37 2 >95  
6 
 
0100 37 5 >95 49 
7 
 
1000 37 2.5 040 50 
8 
 
1000 37 2.5 >95 
 
51 
Table 2. Conjugation of nucleophiles with GFP (S147C, Sulf) 42 
[a] Determined by ratio of peak heights in deconvoluted mass spectrum. 
 
48 
An excess of phenyl selenol (100 eq.), a soft nucleophile similar to thiol, reacted 
rapidly with GFP (S147C, Sulf) 42 to afford the mixed thio/seleno bisether 49 in 
excellent conversion (Table 2, Entry 6) after incubation for 5 h at 37 °C. Whilst most 
amines failed to react with sulfonium 42 at pH 8 because of their high pKa values, 
phthalimide did undergo reaction, forming 50 in 40 % yield after 2.5 h at 37 °C, 
while unreacted sulfonium 42 was also observed (Table 2, Entry 7). Interestingly, 
incubation of GFP (S147C, Sulf) 42 with sodium azide (1000 eq.) 2.5 h at 37 °C 
generated an azide labelled GFP (S147C, Azide) 51 in complete conversion (Table 2, 
Entry 8).  
The ability to generate GFP (S147C, Azide) 51 was interesting as the azide group 
represents a handle for further protein modification using well established  ‘click 
chemistry’.145  
 
Scheme 46. One pot conversion of GFP (S147C) 32 to GFP (S147C, Azide) 51, 
followed by strain-promoted click reaction 
49 
With this in mind, a one pot method for conversion of the exposed cysteine residue 
on GFP (S147C) 32 to an azide handle GFP (S147C, Azide) 51 was developed. 
Incubation of GFP (S147C) 32 with 2,5-dibromohexanediamide 14 (50 eq., 2 h, 
37 °C) followed by addition of sodium azide (sat. solution 100 µL/ mg of protein, 2 
h, 37 °C) resulted in a clean conversion to GFP (S147C, Azide) 51. The applicability 
of the azide reactive handle was analysed using strain-promoted azide-alkyne 
activated click chemistry (SPAAC).
145 
Gratifyingly, treatment of 51 with a model 
strained octyne 52 (synthesised by Antoine Maruani, PhD Student, Caddick Group) 
afforded triazole product 53 in complete conversion (Scheme 46). 
 
2.8 Dual modification 
The ability to control the propensity of sulfonium to form dehydroalanine, by careful 
positioning of a cysteine residue in the structure of GFP, highlighted the potential of 
this approach to deliver substrate-controlled chemical protein modification. These 
initial observations were explored further to ascertain the possibility of using this 
approach to differentiate between two different cysteine residues on the protein 
surface, whilst introducing two orthogonal reactive groups for further dual protein 
modification. 
2.8.1 Dual cysteine mutants 
Two dual cysteine mutants, GFP (S147C, +CG) 54 and GFP (S147C, T230C, 233Δ) 
55 (Figure 8), were designed to explore bisalkylation of cysteines using 2,5-
dibromohexanediamide 14 to obtain site-selective dual modification.  
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Figure 8. A) Dual Mutants GFP (S147C, +CG) 54 or GFP (S147C, T230C, 
233Δ) 55 B) a) Surface and b) Stick representation of GFP (S147C, T230C, 233Δ) 55 
(α-proton coloured in green) (PDB: 2B3P) 
GFP mutants (S147C, +CG) 54 and GFP (S147C, T230C, 233Δ) 55 were designed, 
cloned and expressed using standard biochemistry techniques (55 was designed, 
cloned and expressed by Paul Moody, PhD student, Caddick Group). As discussed in 
Section  2.3, the α-proton for cysteine at position 147 was expected to be solvent 
inaccessible (Figure 8B. α-proton coloured in green), whereas the α-protons for 
cysteine residues at +CG and 230 were solvent accessible (Figure 8B. α-proton 
coloured in green).  Prior to all reactions with 2,5-dibromohexanediamide 14, the 
GFP mutants were treated with dithiothreitol (DTT) to reduce any disulfide dimers. 
Excess reducing agent was removed by repeated diafiltration into buffer (sodium 
phosphate, 100 mM, pH 8).  
2.8.2 Reaction of dual mutants with N-methylmaleimide 
To probe the relative reactivity and accessibility of the engineered cysteine residues, 
GFP dual mutants 54 and 55 were incubated with a single equivalent of N-
methylmaleimide at 21 °C under mildly basic conditions (sodium phosphate buffer, 
100 mM, pH 8) and analysed by LCMS after 1 h.  
Due to propensity of cysteine residues of GFP (S147C, +CG) 54 to reoxidize rapidly 
and remain as intramolecular disulfide, reaction with single equivalent of N-
methylmaleimide did not proceed to completion. However, following reduction with 
DTT and incubation with excess N-methylmaleimide (20 eq.), GFP (S147C, +CG) 
51 
54 did react to form dual maleimide labelled GFP (S147C N-methylmaleimide, +CG 
N-methylmaleimide) 56 (Scheme 47).  
 
Scheme 47. Reaction of GFP (S147C, +CG) 54 with N-methylmaleimide 
On the other hand, the reaction of GFP (S147C, T230C, 233Δ) 55  with a single 
equivalent of N-methylmaleimide proceeded to completion giving three 
distinguishable peaks in the mass spectra; i) unreacted GFP starting material, ii) GFP 
linked to single maleimide; and iii) GFP linked to two maleimides, in a 1:2:1 ratio 
respectively (Scheme 48). The 1:2:1 ratio demonstrated the essentially equivalent 
reactivity of the two cysteine residues for GFP (S147C, T230C, 233Δ) 55.  
52 
  
Scheme 48. Reaction of GFP (S147C, T230C, 233Δ) 54 with N-methylmaleimide, 
LCMS spectra and m/z assigned. 
 
2.8.3 Reaction of Dual Mutants with 
2,5-dibromohexanediamide  
Extrapolating from the results reported in Section 2.4, it was anticipated that the 
reaction of cysteine dual mutants GFP (S147C, +CG) 54 and GFP (S147C, T230C, 
53 
233Δ) 55 with 2,5-dibromohexanediamide 14 would yield sulfonium at position 147 
and dehydroalanine at positions +CG and 230 (Scheme 49).  
 
Scheme 49. Expected reaction of mutant GFP (S147C, +CG) 54 and GFP (S147C, 
T230C, 233Δ) 55 with 2,5-dibromohexanediamide 14 
GFP (S147C, +CG) 54 was incubated with the 2,5-dibromohexanediamide 14 (50 
eq., sodium phosphate buffer, 100 mM, pH 8) for 2 h at 37 °C. Surprisingly, LCMS 
analysis indicated an unknown product with a mass increase of 142 Da, the expected 
mass change for conversion of only one cysteine residue to sulfonium. The second 
cysteine residue appeared to have not reacted at all. This was unexpected as the 
reaction of GFP (S147C, +CG) 54 with N-methylmaleimide indicated the presence of 
two cysteine residues (Scheme 47). To analyse if there was any free cysteine thiol, 
the unknown product was subjected to reaction with N-methylmaleimide. On 
incubation with 5 equivalents of N-methylmaleimide for 1 h at 21 °C (sodium 
phosphate buffer, 100 mM, pH 8), this unknown product remained completely 
unchanged. Prior to reduction by DTT, GFP (S147C, +CG) 54 preferred to exist as 
an intramolecular disulfide not reacting with N-methylmaleimide. It was therefore 
hypothesized that this unknown product could be a bisthioether 60 (Scheme 50). This 
indicated that 2,5-dibromohexandiamide 14 reacted with one of the cysteine thiols 
first to form a sulfonium or thioether which was then trapped by the remaining free 
cysteine residue in an intramolecular reaction. To overcome this problem and prevent 
intraprotein reactivity, the molar equivalents of 2,5-dibromohexandiamide 14 were 
54 
increased from 50 to 1500. Gratifyingly, this led to formation of the expected GFP 
(S147C Sulf, +CG Dha) 58.  
 
 
Scheme 50. Reaction of GFP (S147C, +CG) 54 with 2,5-dibromohexanediamide 14 
A) 50 equivalents  B) 1500 equivalents 
The second dual mutant, GFP (S147C, T230C, 233Δ) 55 reacted smoothly with just 
50 equivalents of 2,5-dibromohexanediamide 14 under similar conditions (sodium 
phosphate buffer, pH 8, 2 h, 37 °C) to give the expected dual modified product GFP 
(S147C Sulf, T230C Dha) 59 (Scheme 51).  
Attempts to identify the position of sulfonium and dehydroalanine on the modified 
protein were made using tryptic digest followed by mass spectroscopy. However, 
despite repeated attempts, multiple proteases including trypsin and chemotrypsin 
were found to be inactive towards GFP. 
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Scheme 51. Reaction of GFP (S147C, T230C, 233Δ) 55 with 
2,5-dibromohexanediamide 14 
2.8.4 Dual functionalisation of dual modified GFP 
The observed differential reaction of GFP dual cysteine mutants with 
2,5-dibromohexanediamide 14 represents the first reported instance of substrate-
controlled regioselective, chemical dual-modification of a protein. This differential 
reactivity could potentially be used for the introduction of two orthogonally reactive 
functional groups onto a single protein. The exploitation of differential reactivity 
necessitated a method for orthogonal functionalisation of sulfonium and 
dehydroalanine.  
 
Scheme 52. Conversion of sulfonium to a reactive intermediate followed by 
functionalisation 
Further modification of sulfonium into a different reactive intermediate that allowed 
orthogonal protein functionalisation in the presence of dehydroalanine functionality 
was envisaged (Scheme 52). Conversion of sulfonium into a non-thiol reactive 
functional group would allow facile dual functionalization compatible with thiol 
modification of dehydroalanine.   
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The functional group of immediate interest was azide, as it had already been shown 
that this functionality could be introduced successfully onto GFP (S147C, Sulf) 42 
by ring-opening of sulfonium.  Dehydroalanine residues have been previously 
reported to be functionalized by conjugate addition of thiols,
67,70
 but no previous 
accounts of reaction with azides exist. The inertness of dehydroalanine to azide, was 
the key to the success of this approach, and this was evaluated by incubation of GFP 
(+CG, Dha) 44 and GFP (T230C, Dha) 45 with sodium azide (sodium phosphate 
buffer, pH 8, 2 h, 37°C). Gratifyingly, no reaction was observed indicating that 
dehydroalanine was unreactive to azides (Scheme 53). No reaction was observed 
even after a prolonged reaction time period of 18 h at 15 °C. 
 
Scheme 53. Reaction of GFP (+CG, Dha) 44 and GFP (T230C, Dha) 45 with sodium 
azide 
The inertness of dehydroalanine towards sodium azide afforded the opportunity to 
synthesize site-selectively dual functionalised GFP using dual cysteine mutants 
GFP (S147C, +CG) 54 and GFP (S147C, T230C, 233Δ) 55. Incubation of GFP 
(S147C Sulf, +CG Dha) 58 and GFP (S147C Sulf, T230C Dha) 59 with azide (NaN3, 
>1000 eq, 37 °C, 2 h) resulted in the formation of GFP (S147C Azide, +CG Dha) 61 
and GFP (S147C Azide, T230C Dha) 62, as determined by LCMS (Scheme 54). The 
inertness of dehydroalanine 44 and 45 towards azide (Scheme 53) strongly indicated 
that sodium azide reacts selectively with position 147 sulfonium to generate the 
57 
desired dehydroalanine/azide adduct in preference to an azidoalanine/sulfonium 
adduct. 
 
Scheme 54. Reaction of GFP (S147C Sulf, +CG Dha) 58 and GFP (S147C Sulf, 
T230C Dha) 59 with sodium azide 
Azide/Dehydroalanine constructs 61 and 62 represent an elegant platform for 
orthogonal protein dual functionalisation. The orthogonality and robustness of the 
reactions to gain access to these constructs allowed these reactions to be carried out 
in one-pot without need for intermediate purification steps. Incubation of GFP 
(S147C, +CG) 54 and GFP (S147C, T230C) 55 with 2,5-dibromohexanediamide 14 
(50 eq.) for 2 h at 37 °C under basic conditions (sodium phosphate, 100 mM, pH 8.0)  
followed by treatment with sodium azide (>1000 eq) for 2 h at 37 °C resulted in the 
GFP (S147C Azide, +CG Dha) 61 and GFP (S147Azide, T230 Dha) 62 in a single 
pot reaction (Scheme 55). 
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Scheme 55. One pot conversion of dual mutants GFP (S147C, +CG) 54 and GFP 
(S147C, T230C, 233Δ) 55 to azide/dehydroalanine constructs GFP (S147C Azide, 
+CG Dha) 61 and GFP (S147Azide, T230Dha) 62 
The dual functionalisation of azide/dha constructs 61 and 62 was then pursued. 
Incubation of GFP (S147C Azide, +CG Dha) 61 with excess 2-mercaptoethanol 
(10µL/mg protein, sodium phosphate, pH 8, 100 mM) for 30 min at 37 °C resulted in 
the formation of conjugate 63 (Scheme 56).  After removal of excess thiol using 
diafiltration, reaction with octyne 52 (100 eq., overnight, 21 °C) led to the formation 
of the desired dual functionalized conjugate GFP (S147C Octyne, +CG BME) 64 
(Scheme 56).   
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Scheme 56. Dual functionalisation of GFP (S147C Sulf, +CG Dha) 53 
To test the robustness of this dual functionalisation approach, GFP (S147C Azide, 
T230C Dha) 62 was functionalized in the reverse order. The azide functional group 
was modified using strain-promoted azide-alkyne activated click chemistry (SPAAC) 
145 
by treatment with commercially available strained alkyne fluorophore, 
dibenzylcyclooctyne-PEG4-Fluor-545 65 (100 eq., 4 h, 21 °C). After removal of 
excess fluorophore using diafiltration, the treatment of the resultant fluorophore-
labelled-GFP conjugate 66 with excess 2-mercaptoethanol (10 µL/mg protein, 30 
min, 37 °C) resulted in formation of dual functionalised GFP (S147C Azide 
dibenzylcyclooctyne-PEG4-Fluor-545, T230C Dha 2-mercaptoethanol) conjugate 67 
as the sole product (Scheme 57). It is important to note that this approach of 
functionalisation, i.e. reaction of azide prior to dehydroalanine generally yielded 
cleaner conjugates, as evidenced by LCMS.  
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Scheme 57. Dual functionalisation of GFP (S147C Sulf, T230C Dha) 62 
2.9 Conclusion 
A novel method for the site-selective, dual-labelling of a protein via cysteine 
modification has been developed. The method exploits the reaction of 2,5-
dibromohexandiamide with cysteine residues forming either sulfonium or 
dehydroalanine depending on protein structure and residue microenvironment. It 
provides the first example of the substrate-controlled, dual-modification of a protein. 
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A strategy for orthogonal functionalisation of sulfonium and dehydroalanine residues 
was also developed. The utility of this approach was demonstrated by a model GFP 
cysteine dual mutant that was site-selectively labelled with commercially available 
octyne and thiol probes yielding a homogenous product. Overall, the strategy 
represents a chemoselective dual protein modification method that enables efficient 
and robust dual functionalisation of cysteine side chains using orthogonal reactivity 
under mild conditions underpinned by two sequential chemoselective reactions. This 
approach requires only routine molecular biology techniques and the 
functionalisation can be affected using a wide range of commercially available 
reagents, in a simple and robust manner in a single day. 
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Chapter 3 Cysteine modification to 
thiophosphonium 
3.1 Introduction 
Phosphorus (III)-based reagents exhibit high selectivity towards disulfide bonds and 
have been widely employed as chemical tools for protein modification.  The most 
common application of such reagents is for selective reduction of disulfide bonds in 
proteins and peptides, usually achieved using tris(2-carboxyethyl)phosphine (TCEP) 
(Scheme 58).
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Scheme 58. Tris(2-carboxyethyl)phosphine mediated reduction of disulfides 
Another phosphorus(III)-based reagent, tris(dimethylamino)phosphine 68 exhibits 
similar selectivity for disulfide bonds and has been reported to be an efficient 
desulfurizing agent for small molecule substrates.
56,152,153,154
 Harpp et al. 
demonstrated rapid and selective desulfurization of disulfides using 
tris(dimethylamino)phosphine 68 to the corresponding thioethers in near-quantitative 
yield (Scheme 59A).
154
 The reaction has been proposed to proceed via 
thiophosphonium intermediate (Scheme 59B). 
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Scheme 59. A) Conversion of disulfides to thioethers B) Proposed mechanism via 
displacement of thiophosphonium
 
Davis et al. used tris(dimethylamino)phosphine 68 for the conversion of a disulfide 
linked glycoprotein 73 into thioether linked glycoprotein 74 under basic conditions 
(pH 9.5) (Scheme 60A).
155
 Mechanistic investigations of this reaction with a model 
disulfide linked glycosyl amino acid 75 revealed loss of stereochemical information 
at the α-carbon, yielding the thioether product 76 as a mixture of diastereoisomers 
(Scheme 60B). The retention of the anomeric configuration suggested that the 
stereodivergence resulted from the racemization of α-proton of the cysteine residue. 
Thus, the reaction mechanism was hypothesized to proceed via a dehydroalanine 
intermediate 78 formed by β-elimination of thiophosphonium 77. The thioether 
product 76 was obtained presumably via conjugate addition of glycosyl thiol onto 
Dha (Scheme 60C).  
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Scheme 60. Reaction of tris(dimethylamino)phosphine 68 with A) disulfide linked 
glycoprotein 73 B) disulfide linked glycosyl amino acid 75 C) Mechanism of 
transformation of disulfide to thioether via Dha intermediate 
Thiophosphoniums are activated species that have the potential to provide access to 
previously unattainable chemical modifications. Krafft et al. demonstrated 
displacement of thiophosphonium 80 from chiral carbon centers by a range of 
nucleophiles including phthalimide, bromide and azide (Scheme 61). 
156
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Scheme 61. Displacement of thiophosphonium by phthalimide
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The displacement reactions, reported for a variety of secondary and primary 
thiophosphonium substrates, proceeded with an inversion of configuration at the 
carbon α to the thiophosphonium linkage. The reaction was proposed to proceed via 
an SN2 pathway.
156
 The displacement reactions were typically carried out under dry 
conditions in a polar solvent by heating at 60 °C for 6 h, leading to high yields.  
  
3.2 Aims 
A major aim of this work was to explore the mechanism of the reaction of disulfides 
with tris(dimethylamino)phosphine 68 and to provide evidence for existence of 
thiophosphonium species. This work also sought to isolate the thiophosphonium 
species to evaluate its stability, ease of access and reactivity for protein 
bioconjugation. 
The reaction of cysteine based disulfide substrates with 
tris(dimethylamino)phosphine 68 to form thioethers can proceed via two pathways 
(Scheme 62):  
Pathway A: Step 1 involves reaction of phosphine 68 with a disulfide 82, forming a 
thiophosphonium 83 intermediate and releasing the corresponding thiol.  In step 2, 
the thiophosphonium 83 then undergoes a SN2 type substitution reaction forming 
thioether 84 with retention of stereochemistry (Scheme 62); or 
Pathway B: Step 1 again involves reaction of phosphine 68 with a disulfide 82, 
forming a thiophosphonium 83 intermediate and releasing the corresponding thiol. 
66 
Under basic conditions, however, the thiophosphonium intermediate 83 undergoes 
β-elimination to form dehydroalanine 85 (Step 2).155 In step 3, conjugate addition of 
a thiol to dehydroalanine 85 forms thioether 86 with the loss of stereochemical 
information (Scheme 62).  
 
Scheme 62. Pathways for the conversion of disulfide into a thioether 
While both reaction pathways have been proposed, no evidence for the existence of 
the thiophosphonium species, to the best of our knowledge, is available.  Further 
investigations may prove informative and provide access to thiophosphonium as a 
highly reactive intermediate that could serve as a platform to access to a range of 
previously unattainable functionalities. This would find plentiful applications in 
proteomics, protein modification and protein therapeutics. The displacement of 
thiophosphonium via a SN2 type displacement reaction could also allow access to 
stereochemically homogenous post-translational mimics (PTMs) that are unattainable 
by dehydroalanine functionalization.
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Scheme 63. Access to novel homogenous amino acids or PTMs via thiophosphonium  
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To access thiophosphonium 83, it would be essential to prevent step 2 in the reaction 
sequence for both pathways A and B, as shown below (Scheme 62).  
 
Scheme 64. Formation of stable thiophosphonium intermediate 
Pathway A could be shut down by employing a suitably biased alkyl-aryl disulfide, 
such that the released aromatic thiol would be less likely to participate in the 
displacement reaction owing to its poorer nucleophilicity. This is likely to be a 
favourable alteration as previous literature reports indicate the preferential attack of 
phosphine on the sulfur that results in the release of the most stable and therefore the 
least nucleophilic thiolate (Scheme 65).
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Scheme 65. Reaction of alkyl-aryl disulfide with tris(dimethylamino)phosphine 68   
Pathway B, or β-elimination of thiophosphonium 83 to dehydroalanine 85 has been 
reported to occur under basic conditions (pH 9.5). Hence, we postulate that pH 
control would allow isolation of a thiophosphonium species. In view of the results 
obtained in  Chapter 2, it should also be noted that substrate control could also 
prevent the formation of dehydroalanine.  
68 
The following aims were identified for this project: 
1. To investigate evidence for thiophosphonium intermediate following reaction 
of a disulfide with tris(dimethylamino)phosphine; 
2. To design a suitable alkyl-aryl disulfide system and isolate the subsequent 
thiophosphonium species;  
3. To investigate the stability of thiophosphonium species under aqueous 
conditions; and 
4. To investigate the reactivity of thiophosphonium intermediates towards 
nucleophiles and thus to determine the suitability of this approach for protein 
modification. 
3.3 Reaction of disulfides with 
tris(dimethylamino)phosphine 
3.3.1 Small molecule model system  
The reaction of disulfides with tris(dimethylamino)phosphine 68 was investigated 
initially on small molecule model system as it affords greater mechanistic insight and 
facile detection of the thiophosphonium species.  
Pathway A 
To probe the proposed reaction pathway A (Scheme 64), dodecanethiol was chosen 
as the alkyl component of the model disulfide. The lack of an acidic α-proton 
blocked reaction pathway B (Scheme 66) and therefore allowed exclusive analysis of 
reaction pathway A. High boiling point of dodecanethiol also simplified isolation of 
products.  To prove that the reaction indeed proceeded through a thiophosphonium 
intermediate, step 2 was sought to be inhibited by employing a suitable alkyl-aryl 
disulfide (Scheme 66). The aryl thiol component of the disulfide was chosen to be 
5-mercapto-2-nitrobenzoic due to its widespread use in biochemistry through 
Ellman’s reagent. 
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Scheme 66. Formation of stable thiophosphonium intermediate 
Disulfide 96 was synthesized in 30% yield by the reaction of dodecanethiol 95 with 
excess Ellman’s reagent in the presence of potassium carbonate as a base (Scheme 
67). 
 
Scheme 67. Synthesis of disulfide 96  
The reaction of disulfide 96 with tris(dimethylamino)phosphine 68 at 21 °C (in 
DMSO or acetonitrile) led to an instantaneous colour change of the reaction mixture 
from colourless to red, indicating release of 5-mercapto-2-nitrobenzoic acid (Scheme 
68). Unlike with alkyl-alkyl disulfide substrates,
154
  no thioether 98 was isolated or 
detected in the reaction mixture after 1 h at 21 °C. The reaction indicated that a 
suitably designed alkyl-aryl disulfide system can inhibit displacement of 
thiophosphonium species by the released thiol (Pathway A, Step 2, Scheme 64). 
70 
 
Scheme 68. Reaction of disulfide 96 with tris(dimethylamino)phosphine 68 leads to 
formation of thiophosphonium 97 but no thioether 98 
Successful inhibition of reaction pathway A provided an excellent opportunity for 
potentially detecting thiophosphonium 97 in the reaction mixture. The reaction 
mixture was probed for evidence of 97 using 
31
P NMR spectroscopy after 1 min at 
21 °C. The 
31
P NMR spectrum of the reaction mixture was compared against a pure 
sample of dodecanethiophosphonium tetrafluoroborate 101 that was synthesized via 
an alternative route (Scheme 69).
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Scheme 69. A) Synthesis of t-butyl hypochlorite B) Synthesis of dodecane 
thiophosphonium tetrafluoroborate salt 101 
157 
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The reaction mixture positively indicated the presence of a thiophosphonium species 
97 (Figure 9) (δ 66.9 ppm). However, the product was not exclusive, with a number 
of other phosphorus species including tris(dimethylamino)phosphine 68 (δ 123.2 
ppm), hexamethylphosphoramide (δ 24.1 ppm)  and related oxidation products (δ 
13.9 ppm and δ 8.8 ppm)  also being observed. An unknown peak (δ 62.5 ppm), was 
also observed close to the thiophosphonium species which will be discussed later in 
the chapter.   
A. 
 
 
B.  
 
Figure 9. 
31
P NMR spectra A) Thiophosphonium 97 B) Thiophosphonium 101 
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Pathway B 
To probe proposed reaction pathway B (Scheme 64), protected cysteine was chosen 
as the alkyl component of the model disulfide. The presence of an acidic α-proton is 
likely to cause the reaction to proceed via pathway B, as previously reported.
155
 To 
prevent the formation of thioether 106 (Step 3, Pathway B), alkyl-aryl disulfide with 
5-mercapto-2-nitrobenzoic acid as the aryl thiol component was employed (Scheme 
70).  
 
Scheme 70. Reaction pathway for reaction of disulfide 102 with 
tris(dimethylamino)phosphine 68 
Disulfide 108 was synthesized by reaction of cysteine 107 with excess Ellman’s 
reagent in buffer (phosphate buffer, 100 mM, pH 8.0) in a modest yield of 33% 
(Scheme 71). Excess Ellman’s reagent was required to minimize the reaction of 
unreacted cysteine 107 with product disulfide 108.  
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Scheme 71. Synthesis of model disulfide 108 
The treatment of disulfide 108 with tris(dimethylamino)phosphine 68  under basic 
conditions (CHES/MES buffer, 70 mM, pH 9.5) yielded dehydroalanine 110 in a 
respectable 45% yield (Scheme 72), indicating that the reaction proceeds via pathway 
B as expected. The poor nucleophilicity of the released aryl thiolate obviates step 3, 
and thus no thioether 111 was detected in the reaction mixture (Scheme 72). 
31
P NMR indicated no evidence of thiophosphonium species. 
To isolate thiophosphonium 109, Step 2 (Pathway B, Scheme 70) was sought to be 
blocked by control of pH to prevent elimination of thiophosphonium 109 to 
dehydroalanine 110 (Scheme 72). The reaction of disulfide 108 with 
tris(dimethylamino)phosphine 68 was repeated at lower pH (phosphate buffer, 100 
mM, pH 8.0). Unfortunately, however, no trace of thiophosphonium 109 could be 
observed or isolated, and dehydroalanine 110 was isolated yet again in 50% yield 
(Scheme 72). Various attempts to prevent elimination of thiophosphonium 109 to 
dehydroalanine 110 under different pHs (5.0, 6.0, 7.0) failed. Surprisingly, pH 
measurement of the reaction mixture subsequent to addition of 
tris(dimethylamino)phosphine 68 indicated that the reactions were under highly basic 
conditions(pH 14). At the concentration required for small molecule reactions, buffer 
strength was found to be insufficient for these experiments, hence no evidence of 
thiophosphonium 109 could be obtained.  
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Scheme 72. Conversion of disulfide 108 to dehydroalanine 110 
3.4 Protein model system 
Unlike small molecule reactions, protein bioconjugation reactions are carried out at 
much lower (micromolar) concentrations and therefore afford greater control over 
pH variations. The formation of thiophosphonium was hence analysed on a protein 
model system. Single cysteine mutant GFP (S147C) 32 (Section  2.3) was used as a 
model system to investigate the reactivity of a disulfide with 
tris(dimethylamino)phosphine 68 and explore thiophosphonium formation on a 
protein. The reaction was unlikely to proceed via Pathway B (Scheme 64), i.e., 
elimination of thiophosphonium to dehydroalanine, due to the presence of a solvent 
inaccessible α-proton as observed in  Chapter 2 in case of the strong resistance of 
activated sulfonium at position 147 to undergo β-elimination. As with the small 
molecule system, 5-mercapto-2-nitrobenzoic acid was chosen as the aryl component 
of the the disulfide. 
GFP (S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 112 was synthesized by 
treatment of GFP (S147C) 32 with a single equivalent of Ellman’s reagent under 
basic conditions (phosphate buffer, 100 mM, pH 8.0) for 16 h at 4 °C. LCMS 
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analysis indicated complete formation of GFP (S147C, 5-mercapto-2-nitrobenzoic 
acid) disulfide 112 (Scheme 73). 
 
Scheme 73. Reaction of GFP (S147C) 32 with Ellman’s regent 
GFP (S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 112 (1 mg/ml, phosphate 
buffer, 100 mM, pH 8.0) was then treated with varying equivalents of 
tris(dimethylamino)phosphine 68 (1, 10, 25 or 50 eq.), but LCMS indicated no 
reaction after incubation at 21 °C for 16 h. Increasing the number of molar 
equivalents of 68 (100 and 125 eq.) provided some evidence of GFP (S147C, 
thiophosphonium) 113; however, simultaneous and rapid degradation of the protein 
sample was also observed, evidenced by fragmentation and poor signal in LCMS. 
Increasing the molar equivalents further (200 eq.) led to almost complete degradation 
of the protein and no detection of any protein sample was observed LCMS.   
Interestingly, increasing the concentration of the protein GFP (S147C, 5-mercapto-2-
nitrobenzoic acid) disulfide 112 (5 mg/ml, phosphate buffer, 100 mM, pH 8.0) led 
the reaction to proceed succesfully, indicating presence of GFP (S147C, 
thiophosphonium) 113 (65% yield by LCMS) after incubation with 68 (40, 60 and 80 
equivalents) at either 4 °C or 21 °C for 10 min (Scheme 74). In addition to 
thiophosphonium 113, GFP (S147C) 32 was also detected. No significant difference 
in yield was observed when 40, 60 or 80 equivalents of 
tris(dimethylamino)phosphine 68 were used. 
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Scheme 74. Reaction of GFP (S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 112 
with tris(dimethylamino)phosphine 68 
Furthermore, the LCMS analysis of the reaction mixture after a 2 h period indicated 
complete consumption of GFP (S147C) 32 and the formation of GFP (S147C) 
disulfide dimer 114 (Scheme 75A). No formation of dimer 114 was detected by 
incubating GFP (S147C) 32 in the absence of 68 under the reaction conditions 
(phosphate buffer, 100 mM, pH 8.0), indicating that the formation of GFP (S147C) 
disulfide dimer 114 proceeded via the reaction of GFP (S147C) 32 with 
GFP (S147C, thiophosphonium) 113 (Scheme 75B). 
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Scheme 75. A) Reaction of GFP (S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 
112 with tris(dimethylamino)phosphine 68 after 2 h B) Mechanism of formation of 
GFP (S147C) disulfide dimer 114 
Significantly, no GFP (S147C, Dha) 115 or GFP (S147, 5-mercapto-2-nitrobenzoic 
acid) thioether 116 was observed (Scheme 76) indicating that step 2 of both reaction 
pathways A and B were inhibited (Scheme 64). 
 
 
Scheme 76. Reaction of GFP (S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 112 
with tris(dimethylamino)phosphine 68 
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3.5 Thiophosphonium stability  
The stability of thiophosphonium species under aqueous conditions was critical for 
its applicability as a reactive intermediate for protein bioconjugation. Tris(2-
carboxyethyl)phosphine relies on rapid hydrolysis of thiophosphonium formed on 
reaction with a disulfide for efficient reduction to free cysteine.  
Interestingly, 
31
P NMR spectroscopy in D2O revealed that thiophosphonium species 
97 and dodecanethiophosphonium tetrafluoroborate 101 were strongly resistant to 
hydrolysis with no change being observed after 24 h at 21 °C, perhaps indicating that 
the thiophosphonium is stabilized by the three amino group ligands on phosphorus. 
GFP (S147C, thiophosphonium) 113 exhibited similar stability, and could be 
detected after 24 h following storage at 4 °C.  Under similar conditions, however, 
tris(dimethylamino)phosphine 68 degraded rapidly, indicating that the phosphine 
species was very short lived in an aqueous environment, thus explaining the need for 
a large excess of tris(dimethylamino)phosphine 68 in the reaction with model 
disulfides  96, 108 and 112.  
3.6 Mechanistic insights 
The aqueous stability of the thiophosphonium species indicated its suitability for 
protein functionalisation. The poor aqueous stability of tris(dimethylamino) 
phosphine 68, however, made it difficult to access the thiophosphonium species. 
Thus, aqueous conditions often necessitated the use of excess tris(dimethylamino) 
phosphine 68, leading to a rapid increase in pH of the reaction mixture and therefore 
making it unsuitable for general protein modification. 
Furthermore, thiophosphonium 97 and GFP (S147C, thiophosphonium) 113 were 
often accompanied by a number of side products including GFP (S147C) 32 and 
GFP (S147C) disulfide dimer 114 respectively. 
In addition to Scheme 62, the following reaction mechanism parameters can be used 
to account for the observed reaction outcomes: 
1. Reversibility:  The reaction of GFP (S147C) 32 with GFP (S147C, 
thiophosphonium) 113 to form GFP (S147C) disulfide dimer 114 (Scheme 
79 
75B) indicated that step 1, i.e. reaction of tris(dimethylamino)phosphine 68 
with disulfides, involves reversible formation thiophosphonium intermediate 
and a free thiol (Scheme 62). To achieve a greater concentration of 
thiophosphonium, it was essential that the thiol released from step 1 is a poor 
nucleophile (aromatic thiol) (Scheme 77). 
 
Scheme 77. Reaction of tris(dimethylamino)phosphine with disulfide  
2. Stability: While thiophosphonium species exhibit excellent stability, 
tris(dimethylamino)phosphine 68 degrades rapidly under aqueous conditions. 
For alkyl-alkyl disulfides, under non-aqueous conditions, step 1 of the 
reaction with 68 is under equilibrium until thiophosphonium gets trapped as 
the irreversible thioether product. Under aqueous conditions however, the 
rapid degradation of 68 shifts the equilibrium to the left, leading to a lower 
concentration of thiophosphonium available for displacement. For alkyl aryl 
disulfides, this has limited effect, provided that no free alkyl thiols are present 
in the system.  
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Scheme 78. Reaction pathway of tris(dimethylamino)phosphine 68 with disulfide A) 
Non-aqueous environment B) Aqueous environment 
  
3. Position of attack: The formation of GFP (S147C) 32 in the reaction of GFP 
(S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 112 with 
tris(dimethylamino)phosphine 68 indicates that the attack of phosphine  does not 
occur exclusively on the alkyl sulfur. In retrospect, the unidentified species (δ 
62.4 ppm) observed in the reaction between disulfide 96 and 68 (Scheme 67B) 
was thought to be arylthiophosphonium 121 (Scheme 80B). To confirm that this 
unidentified species was indeed arylthiophosphonium 121, Ellman’s disulfide  
was treated with tris(dimethylamino)phosphine 68 and incubated for 10 min at 
21 °C (Scheme 79A). 
31
P NMR of the reaction mixture indicated the formation of 
the major peak very close to the unidentified species at δ 61.6 ppm. In absence of 
any 
31
P NMR data for arylthiophosphonium species in the literature, further 
evidence was obtained about the unidentified 
31
P NMR signal by synthesizing 
benzenethiophosphonium salt 120 of the commercially available thiophenol via 
alternative pathway
157
 which gave 
31
P NMR signal in a similar region (δ 61.9 
ppm) (Scheme 79B).  
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Scheme 79. A) Reaction of Ellman’s reagent with tris(dimethylamino)phosphine 68 
B) Synthesis of benzenethiophosphonium tetrafluoroborate 120 
 
A. 
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B.  
 
 
C.  
 
Figure 10. 
31
P NMR spectra for A)Thiophosphonium 97 B) Reaction of Ellman’s 
disulfide with 68 C) Benzenethiophosphonium tetrafluoroborate 120 
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Whilst previous literature reports indicate the preference of the phosphine attack 
on the sulfur that results in the release of the most stable thiolate, and not on the 
most electropositive sulfur atom, the detection of two different thiophosphonium 
species by 
31
P NMR indicated that the reaction proceeds via attack at both sulfur 
atoms (Scheme 80). In fact, a subsequently released publication indicated a 
similar mode of reactivity.
70
 
 
Scheme 80. Possible reaction pathways – attack of tris(dimethylamino)phosphine 68 
on disulfide 96 
This leads to the release of free alkyl thiol in the reaction mixture, and the amount of 
available thiophosphonium is reduced by the stability effect discussed in the previous 
section. 
3.6.1 Thiophosphonium reactivity with nucleophiles 
Due to the inability to isolate any thiophosphonium species cleanly, displacement 
reaction with nucleophiles (Scheme 63) was likely to proceed sub-optimally. Despite 
this, displacement of thiophosphonium 97 with bromide as nucleophile was 
attempted as a proof of principle reaction. Disulfide 96 was treated with 
tris(dimethylamino)phosphine 68, followed by excess sodium bromide under 
aqueous conditions in a one-pot reaction. Following incubation of the reaction at 
60 °C for 6 h dodecanebromide 122 was successfully isolated in 17% yield (Scheme 
81). 
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Scheme 81. One pot conversion of disulfide 96 to dodecanebromide 122 
This reaction demonstrated the proof of concept of converting a disulfide into a 
stable thiophosphonium species which could undergo a displacement reaction in 
aqueous conditions, albeit in poor yield.  The displacement of thiophosphonium with 
bromide was then attempted on the protein system. GFP (S147C, 5-mercapto-2-
nitrobenzoic acid) disulfide 112 (1 mg/ml, phosphate buffer, 100 mM, pH 8.0) was 
incubated with tris(dimethylamino)phosphine 68 (60 equivalents, in 5 µL DMF) for 
2 hours at 21 °C, followed by incubation with sodium bromide (1000 equivalents, 5 
µL in water) for 4 h at 37 °C. Unfortunately, no GFP (S147C, bromoalanine) 123 
could be detected, and a number of unidentifiable products were detected by LCMS 
(Scheme 82).  
 
Scheme 82. Reaction of GFP (S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 112 
with tris(dimethylamino)phosphine 68 and sodium bromide 
 
3.7 Conclusion 
A novel method for protein functionalisation via a thiophosphonium species was 
evaluated. The reaction of disulfides with tris(dimethylamino)phosphine forming 
thioethers was investigated as a platform to provide access to thiophosphonium 
species.  
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Novel strategies to isolate thiophosphonium species were designed and evaluated on 
model small molecule and protein systems. Alkyl-aryl disulfides were found to 
provide facile access to thiophosphonium species as a reactive intermediate, albeit in 
a non-selective manner. The reaction of tris(dimethylamino)phosphine with 
unsymmetrical alkyl-aryl disulfides was observed to be preferential, but not 
completely selective for attack on the least electrophilic sulfur atom. 
The stability and reactivity of the thiophosphonium intermediate was studied on 
small molecule and protein model systems. Thiophosphonium species was found to 
be stable for at least 24 h under slightly basic, aqueous conditions. The viability of 
thiophosphonium-derived functionalisation, including the various challenges 
involved in synthesising and functionalising thiophosphonium intermediates was also 
investigated. Whilst the thiophosphonium species has potential as a platform for 
protein functionalisation, the difficulty in accessing the thiophosphonium species in a 
selective and high yielding manner presents a major challenge. 
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Chapter 4 Reversible cysteine 
modification using bromomaleimides  
4.1 Introduction 
Bromomaleimides represent a novel class of reagents that react rapidly and 
selectively with cysteine residues on proteins and peptides to afford thiomaleimides 
(Scheme 83). In a reducing environment, such as an excess of 
tris(2-carboxyethyl)phosphine (TCEP) or 2-mercaptoethanol, thiomaleimides can be 
converted back to free thiols (Scheme 83). 
47
 
 
Scheme 83. Reversibility of thiomaleimides 126 and dithiosuccinimides 127 
This quantitative, reversible protein modification is of general interest for 
applications in chemical biology and proteomics. Previous work in this laboratory 
has demonstrated the utility of the thiomaleimide reversibility by introducing a 
bromomaleimide-based biotin affinity tag 128 onto a single cysteine mutant Grb2-
SH2 domain (L111C)  124 and validating the concept of pull down experiments using 
neutravidin beads (Scheme 84).
158
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Scheme 84.  Cleavable biotinylation of Grb2-SH2 domain (L111C) 124 using 
thiomaleimides
158
 
4.2 Aims 
Despite the utility of reversible protein modification of cysteine via thiomaleimide, 
their application is restricted by the requirement for a large excess of reducing agent 
to facilitate reversibility. These conditions are likely to be incompatible with 
disulfide bonds which play a significant role in maintaining the structural integrity of 
proteins.
159
 Employment of reducing conditions to affect reversibility could also lead 
to unfavourable protein folding, aggregation or disulfide scrambling.
160
  The use of 
such harsh conditions for cleaving thiomaleimide to free cysteine poses a challenge 
to the general applicability of the thiomaleimide reversibility approach. Thus, the 
development of efficient, selective and milder reversibility conditions would 
represent a significant improvement over the existing methodology.  
88 
Mechanistically, the reversibility of thiomaleimides with excess thiols can be 
explained by the proposed mechanism outlined below (Scheme 85):  
Step 1: Reaction of thiomaleimide 130 with a single equivalent of thiol proceeds 
rapidly to form the dithiosuccinimide 131.
48
 In an environment of excess thiol, 
however, dithiosuccinimides have been reported to be unstable, indicating that the 
process is under equilibrium.
48
 It is proposed that the dithiosuccinimides are unlikely 
to be stable because of the low pKa of the succinimide proton. The reverse reaction 
can proceed via the elimination of the acidic succinimide proton under mildly basic 
conditions.  
Step 2: In the presence of an excess thiol, it is proposed that unstable 
dithiosuccinimide 131 undergoes thiol exchange. The reaction is proposed to proceed 
via elimination of acidic succinimide proton releasing the free cysteine 107 and 
formation of the dithiosuccinimide 132. An excess of thiol thus pushes the 
equilibrium to the right (Scheme 79). 
 
Scheme 85. Proposed mechanism for reversibility of thiomaleimide 130 
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Based on this understanding of the reaction mechanism, three distinct approaches 
were designed for the development of an improved thiomaleimide reversibility 
approach: 
1. Nucleophile screen: A significant drawback of the current methodology is use of 
disulfide reactive reagents such as 2-mercaptoethanol or TCEP. Reagents which 
do not react with disulfide bonds, but can convert thiomaleimide to free cysteine 
would represent a significant improvement over the existing methodology. A 
number of nucleophiles, including non-thiol nucleophiles such as carbon 
nucleophiles, amines and azides were to be evaluated as potential reagents for 
conversion of thiomaleimide to free cysteine. It is proposed that these 
nucleophiles may offer differential reactivity patterns towards thiomaleimides and 
disulfides which could be exploited for the development of an improved 
reversibility protocol. 
 
2. Cycloaddition reactions: The true potential of thiomaleimide based cysteine 
modification can be realised with the development of a reversibility protocol that 
is orthogonal to disulfide reduction. As maleimides are excellent cycloaddition 
partners that undergo cycloaddition reactions with 1,3-dipoles including azides
161
 
and nitrile oxides,
162 
this affords an opportunity for the development of a 
thiomaleimide reversibility protocol. It is proposed that cycloaddition reaction of 
1,3-dipoles with thiomaleimide might lead to the formation of an intermediate 
cycloadduct 133 that could undergo rapid aromatisation releasing free cysteine 
107 (Scheme 86). This approach was expected to be orthogonal to disulfide 
reduction and likely to react exclusively with thiomaleimide. 
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Scheme 86. Proposed route for conversion of thiomaleimides to cysteine using [3+2] 
cycloaddition reaction 
3. Tether reagents: The optimisation of the existing protocol for conversion of 
thiomaleimide to free cysteine by decreasing the amount of reducing agent would 
also represent a significant improvement and lead to enhanced applicability of this 
approach, especially for protein systems with sensitive disulfide bonds. The 
proposed mechanistic considerations indicate that the pKa of the dithiosuccinimide 
protons play a significant role in the reversibility of thiomaleimides to free thiols 
(Scheme 85). The control of the equilibrium in step 2 of the proposed mechanism 
is vital to developing an improved cleavage approach (see step 2 - Scheme 85). It 
is therefore proposed that thiosuccinimide conjugates lacking acidic proton would 
be stable to any further transformation by thiols. Thus, a tether approach is 
envisaged using bidentate thiol nucleophiles which could form spiro-cylic adducts 
136 (Figure 11) by trapping the reactive dithiosuccinimides into a stable, 
unreactive adduct. 
 
Figure 11. Reactivity of thiosuccinimides  
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The following aims were identified: 
1. To design and develop a small molecule and a protein model system to 
investigate the conversion of thiomaleimide to free thiol; 
2. To screen non-thiol nucleophiles for reactivity with thiomaleimide to afford 
free thiol; 
3. To develop a cycloaddition strategy for an orthogonal thiomaleimide 
reversibility protocol. 
4. To develop a tether-type strategy to improve the existing thiomaleimide 
reversibility protocol;  
4.3 Model system 
4.3.1 Small molecule model system 
Protected cysteine derivative 107 was chosen as a small molecule model system 
(Scheme 88). Its solubility in organic and aqueous solvents allowed simple isolation 
and purification by standard chromatographic techniques. 
Bromo-N-methylmaleimide 125 was chosen as a model bromomaleimide reagent for 
evaluation. It was synthesized by bromination of N-methylmaleimide followed by 
elimination of HBr in 89% yield (Scheme 87).
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Scheme 87. Synthesis of bromo-N-methylmaleimide 125 
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Small molecule model thiomaleimide 130 was synthesized by the reaction of 
cysteine derivative 107 with bromo-N-methylmaleimide 125 in methanol with 
sodium acetate as base. The reaction was complete in 10 min affording 
thiomaleimide 130 in 84% yield (Scheme 88). 
 
Scheme 88. Reaction of bromo-N-methylmaleimide 125 with cysteine 107 
A model disulfide, cystine 139, was synthesized from the corresponding cysteine 107 
in 97% yield using iodine as oxidant (Scheme 89).
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Scheme 89. Cysteine 107 oxidation to cystine 139 
 
4.3.2 Protein model system 
Previous investigations of bromomaleimide and thiomaleimide reactivity have been 
carried out using single cysteine mutant Grb2-SH2 Domain (L111C) 124.
48
 For 
consistency and ease of direct comparison of results, all investigations were carried 
out using the same protein. Thiomaleimide 126 was synthesized by treatment of 
Grb2-SH2 domain (L111C) 124 with a single equivalent of bromo-N-
methylmaleimide 125 for 1 hour at 4 
o
C (Scheme 90). 
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Scheme 90. Reaction of Grb2-SH2 domain (L111C) 124 with 
bromo-N-methylmaleimide 125 
4.4 Reversibility of thiomaleimides 
4.4.1 Thiomaleimide reversibility with nucleophiles 
The reaction of a wide range of non-thiol based nucleophiles with thiomaleimides 
was investigated. Model thiomaleimide 130 was incubated with excess nucleophile 
(100 eq.) for 24 h at 37 
o
C under mildly basic conditions (phosphate buffer, 100 mM, 
pH 8.0) (Table 3) and the reaction was analysed by TLC for release of free cysteine 
107. DMF was used for solubilizing organic molecules into the buffer solution.  
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Entry Nucleophile Reaction outcome / Product  
1 
 
 
No reaction  
2 
 
 
No reaction  
3 
 
 
No reaction  
4 
 
 
No reaction  
5 
 
 
 
6 
 
 
No reaction  
95 
7 
 
No reaction  
8 
 
 
No reaction  
9 
 
 
No reaction  
10 
 
 
No reaction 
 
11 
 
 
 
 
Table 3. Reaction of thiomaleimide 130 with nucleophiles. 
a
10 eq, 21 °C, 2h  
b
Crude  
Amines represented a class of reagents that are excellent nucleophiles and have not 
previously been reported to react with disulfides (Table 3 – Entry 1-3). 
Unfortunately, however, no reaction was reaction was detected following incubation 
with thiomaleimide 130 with amines 140, 141 and 142 after 24 hours at 37 °C. 
Carbon-based nucleophiles such as nitroethane 143, 2-nitropropane 144 and 
diethylmalonate 148 have been reported to undergo conjugate addition reactions 
owing to their low pKa.
164
 Meldrum’s acid 146 and Dimedone 147 are also known to 
have an unusually low pKa of 5.
165
 While no reaction was observed on reaction of 
thiomaleimide 130 with most carbon nucleophiles, conjugate addition product of 2-
nitropropane 145 was identified (Table 3 – Entry 4-8) after incubation for 24 hours at 
37 °C. Despite repeated attempts, this product could not be purified. Nonetheless, as 
no release of cysteine 107 was detected, the reaction of 2-nitropropane 144 with 
thiomaleimide 130 was not attempted further. 
96 
No reaction of thiomaleimide 130 with thioacetamide 149 or sodium azide was 
observed (Table 3 – Entry 9-10). Interestingly, reaction of thiomaleimide 130 with 
sodium sulfite (10 equivalents) led to release of cysteine 107 in excellent yield (96%) 
after 2 h at 21 
o
C (Table 3 – Entry 11). Reaction with sodium sulfite was very rapid, 
with starting material thiomaleimide 130 completely consumed after a matter of 
minutes. Sodium sulfite, however, has been reported to react with disulfide bonds.
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The reaction of sodium sulfite was evaluated for any preferential reactivity towards 
thiomaleimide 130 over disulfide 139.  
 
Scheme 91. Reaction of sodium sulphite with A) thiomaleimide 130  B) disulfide 139 
Comparative reaction of sodium sulfite with both substrates (Scheme 91) indicated 
some preferential reactivity for thiomaleimide 130 over disulfide 139 (Table 4). In 
the case of thiomaleimide 130, the starting material was completely consumed with 
96% of cysteine 107 being liberated within 5 min. The reaction was relatively slower 
with the disulfide 139, with only 40% conversion of disulfide 139 after the same time 
period (Table 4 - Entry 2). Although some preferential reactivity was clearly 
observed, any selectivity was not expected due to rapid rate of reaction in both cases.  
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 Reactant Equivalents 
of Na2SO3 
Time 
(min) 
Conversion Yield 
     
 
10 5 100% 96% 
     
 
10 5 40% 24% 
     
 
Table 4. Reaction of sodium sulfite with thiomaleimide 130 and disulfide 139 
The reaction of sodium sulfite with a Grb2-SH2 domain (L111C) derived 
thiomaleimide 126 was next explored. Thiomaleimide 126 was incubated with 
sodium sulfite under similarly basic conditions (phosphate buffer, 100 mM, pH 8.0). 
The only the product observed by LCMS was that resulting from the addition of 
sulfite to the thiomaleimide 150. No cleavage of the thiomaleimide 126 to yield free 
thiol was observed, even after heating the conjugate for 2 h at 37 
o
C (Scheme 92).  
 
 
Scheme 92. Reaction of thiomaleimide 126 with sodium sulfite 
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The reaction of Grb2-SH2 domain (L111C) derived thiomaleimide 126 with 2-
nitropropane 144 was also attempted. However, no reaction was observed even after 
incubation for 24 h at 37 °C. Thus, this reaction was not studied further. 
4.4.2 Cycloaddition  
Maleimides are electron poor dienophiles/dipolarophiles and therefore excellent 
partners for cycloaddition reactions. Propargyl-allenyl dipoles like azides or nitrile 
oxides react with maleimide in aqueous media forming non-aromatic cyclic 
adducts.
167
 It was thus envisaged that thiomaleimides might undergo similar reaction 
with 1,3-dipoles. It was proposed that the reaction of thiomaleimides with 
nitrile oxide and azide may form non-aromatic cycloadducts 151 or 153, which could 
undergo aromatisation via the loss of the free cysteine 107 (Scheme 93). 
 
Scheme 93.  Proposed cycloaddition reaction outcome of thiomaleimide 130 with A) 
azide B) nitrile oxide 
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The reactivity of thiomaleimide 130 with benzyl azide was evaluated under a range 
of conditions (Scheme 94).   
 
Scheme 94. Reaction of thiomaleimide 130 and bromo-N-methylmaleimide 125 with 
benzylazide 
The reaction of thiomaleimide 130 with the benzyl azide in equimolar amounts at 
room temperature in mixture of methanol and water indicated no reaction following 
incubation for 24 h at 21 
o
C (Scheme 94A). Increasing the number of equivalents of 
benzylazide to 10 also led to no reaction, even after increasing the temperature to 
40 
o
C (Scheme 94A). Similar reaction conditions were applied to the reaction of 
bromo-N-methylbromomaleimide 125 with benzyl azide to assess if it was the 
thioether functionality that precluded the reaction (Scheme 94B). Disappointingly, no 
conversion was observed in this case too. 
Nitrile oxides are more reactive dipoles than azides and are known to react with 
maleimides at room temperatures in aqueous media.
162
 Nitrile oxides can be 
generated in situ from α-chloroaldoximes either by deprotonation in water or by use 
of a base in an organic solvent. Thus the reaction of these 1,3-dipoles with 
thiomaleimides was evaluated. N-hydroxybenzimidoyl chloride, 4-chloro-N-
hydroxybenzimidoyl chloride and 4-bromo-N-hydroxybenzimidoyl chloride (Scheme 
100 
94) were used as a source of nitrile oxides (synthesised by Dr C.C.Lee, Caddick 
Group).  
 
Scheme 95. Reactions of thiomaleimide 130 with α-chloroaldoximes 
Unfortunately, all attempts of nitrile oxide cycloaddition with thiomaleimide 130 
proved to be unsuccessful with a number of unidentifiable products being obtained. 
No cysteine 107 was detected and the approach was not explored further. 
4.4.3 Tether reagents 
Optimisation of the protocol for the conversion of thiomaleimide to free cysteine 
would represent a significant enhancement for the general applicability of 
thiomaleimide reversibility approach. The drawback of the current protocol rests 
with the use of excess reducing agents to affect reversibility. A novel bis-thiol based 
tether strategy was designed to trap the dithiosuccinimide intermediates into spiro-
cyclic adducts 136 (Figure 11). As spiro-cyclic adducts lack an acidic proton, use of 
bis-thiols could eliminate the need for employing excess reducing conditions.  
The utility of bis-thiols as reagents for converting thiomaleimides to cysteine was 
evaluated, initially on a small molecule model thiomaleimide. 1,2-Ethanedithiol (2 
equivalents) was incubated with thiomaleimide 130 for 24 h at 37 
o
C under basic 
101 
conditions (phosphate buffer, 100 mM, pH 8.0). DMF was used for solubilizing 
organic molecules into the buffer solution (Scheme 96). 
 
 
Scheme 96. Reaction of thiomaleimide 130 with 1,2-ethanedithiol  
Whilst free cysteine 107 could not be isolated perhaps due to re-oxidation and/or 
reaction with 1,2-ethanedithiol, stable spirocyclic dithiolane 155 was isolated in 
excellent yields. This transformation demonstrated the proof of concept of using bis-
thiol reagents to trap thiomaleimides into stable dithiolanes, despite having to 
employ a modest excess of the dithiol reagents to compensate for the tendency of 
dithiols to oxidize rapidly to disulfides.
 
Further insight into the mechanism was gained by reaction of 1,2-ethanedithiol with 
bromo-N-methylmaleimide 125, avoiding the interference of released cysteine 107 
from thiomaleimide 130. Interestingly, incubation of bromo-N-methylmaleimide 125 
with 1,2-ethanedithiol yielded a mixture of spirocyclic dithiolane 155 and bicyclic 
bisthioether 156 in a 65:35 ratio after 90 min at 37 
o
C (Scheme 97). Isolation of 
bisthioether 156 followed by heating under the same reaction conditions, however, 
led to complete conversion to the thermodynamic product, dithiolane adduct 155 in 
quantitative yield. 
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Scheme 97. Reaction of A. Bromo-N-methylmaleimide 125 reaction with 
1,2-ethanedithiol B. Conversion of bisthioether 156 to dithiolane 155 
The conversion of bisthioether 156 to dithiolane 155 is proposed to proceed through 
elimination-addition (Scheme 97B). 
The reaction of 1,2-ethanedithiol with thiomaleimides was then investigated on a 
protein model system. Gratifyingly, incubation of thiomaleimide 126 with a single 
equivalent of 1,2-ethanedithiol for 4 h at 37 
o
C resulted in complete conversion to 
free Grb2-SH2 domain (L111C) 124 (Scheme 98A).   
Incubation of Grb2-SH2 domain (L111C) derived thiomaleimide 126 with one 
equivalent of 1,2-ethanedithiol at 21 
o
C or 4 
o
C indicated some liberation of Grb2-
SH2 domain (L111C) 124, however the reaction was far slower. Intermediate 
dithiosuccinimide 157 was more stable at 4 °C and at 21 
o
C consistent with previous 
literature reports (Scheme 98).
48 
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Scheme 98. Reversibility of thiomaleimide 126 using 1,2-ethanedithiol at A) 37 
o
C B) 
4 
o
C to 21 
o
C 
The utility of bis-thiol based protein modification approach was subsequently 
demonstrated with another model protein, single cysteine mutant GFP (S147C) 32 
(cloned and expressed by Paul Moody, PhD student, Caddick group). Incubation of 
GFP (S147C) 32 with bromomaleimide-dec-biotin 158 (synthesised by Chris Ryan, 
Post-Doctoral Research Scientist, Caddick Group) for 1 h at 4 
o
C led to the formation 
of GFP (S147C, biotin-dec-maleimide) 159 in complete conversion. Thiomaleimide 
GFP (S147C, biotin-dec-maleimide) 159 was then treated with stoichiometric 
amount of 1,2-ethanedithiol to facilitate release of free protein.  Gratifyingly, 
incubation for 4 h at 37 
o
C led to a complete release for GFP (S147C) 32 as observed 
by LCMS (Scheme 99). 
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Scheme 99. Reversible modification of GFP (S147C) 32 with biotin-dec-
maleimide 158 
The validity of bisthiol approach was then appraised with a proof of concept pull 
down experiment to establish that 1,2-ethanedithiol was well tolerated for protein 
purification using streptavidin beads. The pull down experiments were carried out in 
collaboration with Paul Moody, PhD student, Caddick group. Fluorescence of GFP 
provided a convenient parameter for the rapid analysis, hence was used as the 
read-out for released protein.  
GFP (S147C, biotin-dec-maleimide) 159 was incubated directly with pre-washed 
streptavidin beads at 37 °C for 4 h (Scheme 100). After the incubation period, the 
unbound GFP (S147C) 32 was removed by thoroughly washing the beads with a 
large volume of PBS buffer solution (3 × 10-fold dilution by diafiltration). 
Incubation of the washed GFP (S147C) loaded streptavidin beads with EDT at 37 °C 
for 4 h resulted in cleavage of GFP (S147C) from the beads. The released GFP 
(S147C) 32 was collected by washing with PBS buffer solution (Scheme 100). 
Fluorescence measurement of the supernatant revealed release of GFP (S147C) 32 
protein from conjugate GFP (S147C, biotin-dec-maleimide) 159, thereby indicating 
the suitability of use of 1,2-ethanedithiol for pull down experiments with the 
bromomaleimide reversibility approach (Figure 12). 
105 
 
Scheme 100. Proof of concept pull down experiment to release GFP (S147C) 32 from 
GFP (S147C, biotin-dec-maleimide) 159 with stoichiometric amount of 1,2-
ethanedithiol  
 
Figure 12. Fluorescence spectra of GFP (S147C) 32 following pull down 
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4.5 Conclusion 
The utility of bromomaleimide based protein modification approach for reversible 
cysteine modification is compromised due to the necessity of using excess reducing 
conditions. Novel strategies for converting thiomaleimide to free cysteine were 
designed and evaluated on model small molecule and protein systems to develop 
improved reversibility protocols.  
A nucleophile screen indicated rapid conversion of thiomaleimide to free cysteine on 
treatment with sodium sulfite. Whilst sodium sulfite was shown was shown to 
preferentially react with thiomaleimide over disulfide, the reaction was found to be 
non-selective. 
A cycloaddition based approach using 1,3-dipoles was also evaluated. The presence 
of bromo and thio functionalities on maleimide led to complete inhibition of 
cycloaddition reaction under conditions suited for protein modification. 
A bis-thiol based tether strategy was designed based on proposed mechanism for 
conversion of thiomaleimide to cysteine, and validated on a small molecule model 
system and a model protein system. Bisthiol reagent 1,2-ethanedithiol was found to 
be highly efficient for conversion of thiomaleimides to free cysteines leading to 
formation of spirocyclic dithiolane. An insight into the reaction mechanism was 
obtained by analysis on small molecule model system. A proof of concept pull down 
experiment was carried out to demonstrate the utility of 1,2-ethanedithiol mediated 
conversion of thiomaleimide to free cysteine. This approach represented a significant 
improvement on the existing methodology and requires only a single equivalent of 
1,2-ethanedithiol. 
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Conclusions and Further Work 
The thesis has desribed and explored three distinct approaches for cysteine 
modification, each of which has been elaborated in separate chapters.  
1. Site-selective dual labelling of proteins 
The first approach for protein modification described in the thesis involves a novel 
method for the site-selective, dual-labelling of green fluorescent protein based on 
‘substrate controlled’ cysteine modification. Two equally reactive cysteine residues 
are modified selectively in a single protein which is then dual labelled with 
orthogonal functional groups. The method exploits the protein micro-environment to 
distinguish reaction outcome of 2,5-dibromohexandiamide with cysteine residues 
forming either sulfonium or dehydroalanine. Further functionalisation of sulfonium 
moiety was carried out selectively via reaction with sodium azide. This provides a 
platform for dual functionalisation.  The protein was then labelled using 
commercially available octyne and thiol probes to yield a homogeneously dual 
labelled protein. The reactions were observed to be highly selective and proceed to 
completion. The evidence for the reactions is obtained throughout using LCMS. 
Overall, the strategy represents an efficient, accesible and robust site-selective, dual 
modification approach.  
Future work on this project should include exploring green fluorescent protein single 
mutants at various positions with differing solvent accessibility values across 
structured and non-structure protein regions with a view to establish a clear 
correlation between solvent accessibility and elimination of sulfonium to 
dehydroalanine. This applicability of this approach for other therapeutic proteins, 
including anticalins and DARPins is likely to be of interest. 
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2. Cysteine modification to thiophosphonium  
The second approach for protein modification described in the thesis involves 
evaluation of thiophosphonium as a platform to access homogeneously modified 
proteins. The reaction of alkyl-aryl disulfides with tris(dimethylamino)phosphine  
was investigated as a simple way to access thiophosphonium species, on small 
molecule and protein systems. Additionally, the evidence for the formation of stable 
alkyl thiophosphonium in reaction of alkyl-aryl disulfides with 
tris(dimethylamino)phosphine was obtained using  
31
P NMR spectroscopy. The 
formation of alkyl thiophosphonium was the predominant pathway; however, it was 
not found to be exclusive as aryl thiophosphonium was also observed. The suitability 
of thiophosphonium as an effective scaffold for protein modification was highlighted 
with stability studies. The viability of thiophosphonium-derived functionalisation, 
including the various challenges involved in synthesising and functionalising 
thiophosphonium intermediates was also investigated. Significant difficulty remains 
in accessing the thiophosphonium species in a selective and high yielding manner. 
It is worthy to note that Davis et al. reported a similar method to access 
thiophosphonium functionality in a recent publication, whilst the work was 
undergoing.
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 Future work on this project should include exploring the use of 
alternative phosphines including tris(diethylamino)phosphine for more selective 
formation of the thiophosphonium species. In addition, functionalisation of 
thiophosphonium by reaction with various nucleophiles including thiol and azide is 
likely to be of interest.   
3. Reversible cysteine modification using bromomaleimides. 
The third approach for cysteine modification described in the thesis involves 
development of bromomaleimide based reversible cysteine modification.  
Bromomaleimide reagents, developed within the Caddick and Baker groups at UCL, 
allow rapid and selective funtionalisation with cysteine residues to afford 
thiomaleimides, that can be converted back to free thiols in the presence of excess 
reducing agents such as tris(2-carboxyethyl)phosphine (TCEP)  and 2-
mercaptoethanol. The majority of this work focussed on the development of 
improved strategies for conversion of thiomaleimides back to free cysteines.  
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Multiple strategies were desgined and evaluated on small molecule and protein 
model system. Of particular note is the discovery that the reaction of stoichiometric 
amount of 1,2-ethanedithiol with thiomaleimide proceeds to form stable spirocyclic 
dithiolanes in near quantitative yield, releasing free thiol. The utility of using bis-
thiols to affect thiomaleimide reversibility was demonstrated in a proof of concept 
pull-down experiment using streptavidin beads. In addition to bisthiols, sodium 
sulfite was shown was shown to preferentially react with thiomaleimide over 
disulfide but the reaction was found to be non-selective. 
Future work on this project should include utility of bisthiol reagents for conversion 
of thiomaleimides to free thiols for applications in chemical biology and proteomics.  
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Experimental 
General Experimental  
Organic Chemistry 
 
 
All reactions were carried out at ambient temperature and under a nitrogen 
atmosphere and at atmospheric pressure unless otherwise stated. Air- and moisture-
sensitive liquids and solutions were transferred via syringe into the reaction vessels 
through rubber septa. All reaction mixtures were stirred magnetically. Reaction 
progress was monitored by analytical TLC using Merck aluminium coated plates 
covered with a 0.2 mm layer of silica gel 60 F254.  Product spots were visualised by 
UV irradiation at 254 nm and subsequent staining with potassium permanganate 
solution, followed by heating. Concentration in vacuo refers to distillation on a Buchi 
rotary evaporator, and where appropriate under high vacuum. Infrared spectra were 
obtained on a Perkin Elmer Spectrum 100 FTIR Spectrometer operating in ATR 
mode with frequencies given in reciprocal centimetres (cm
-1
). Melting points were 
measured with a Gallenkamp apparatus and are uncorrected. Optical rotations were 
measured using a Perkin Elmer 343 polarimeter. Fluorescence was measured using 
Starna Scientific 26.100-F quartz fluorescence cuvette with a 10mm path length. The 
fluorescence spectra were obtained at room temperature using a Cary Eclipse 
Fluorescence Spectrophotometer. The sample was excited at 494nm, and the 
emission intensity was scanned at 120nm/min with an averaging time of 0.5s and a 
data interval of 1nm. The excitation and emission slit was set to 5nm. 
 
Protein Mass Spectroscopy 
LCMS was performed on protein samples using one of the following: 
1. Thermo Scientific uPLC connected to MSQ Plus Single Quad Detector 
(SQD). Column: Hypersil Gold C4 1.9 μm 2.1 x 50 mm. Wavelength: 254 
nm. Mobile Phase: 99:1 Water (0.1% formic acid): MeCN (0.1% formic acid) 
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to 1:9 Water (0.1% formic acid): MeCN (0.1% formic acid) gradient over 4 
min. Flow Rate: 0.3 mL/min. MS Mode: ES+. Scan Range: m/z = 500-2000. 
Scan time: 1.5 s. Data obtained in continuum mode. The electrospray source 
of the MS was operated with a capillary voltage of 3.5 kV and a cone voltage 
of 50 V. Nitrogen was used as the nebulizer and desolvation gas at a total 
flow of 600 L/h. Total mass spectra for protein samples were reconstructed 
from the ion series using the pre-installed ProMass software using default 
settings for large proteins in m/z range 500-1500. 
2.  Waters Acquity uPLC connected to Waters Acquity Single Quad Detector 
(SQD). Column: Acquity uPLC BEH C18 1.7 μm 2.1 x 50 mm. Wavelength: 
254 nm. Mobile Phase: 95:5 Water (0.1% Formic Acid): MeCN (0.1% Formic 
Acid) Gradient over 4 min to 5:95 Water (0.1% Formic Acid): MeCN (0.1% 
Formic Acid). Flow Rate: 0.6 mL/min. MS Mode: ES+. Scan Range: m/z = 85-
2000. Scan time: 0.25 sec. Data obtained in continuum mode. The electrospray 
source of the MS was operated with a capillary voltage of 3.5 kV and a cone 
voltage of 50 V. Nitrogen was used as the nebulizer and desolvation gas at a total 
flow of 600 L/h.Total mass spectra for protein samples were reconstructed from 
the ion series using the MaxEnt 1 algorithm pre-installed on MassLynx software 
Quoted yields determined by ratio of peak heights in deconvoluted mass spectrum 
unless otherwise stated. 
Nuclear Magnetic Resonance (NMR) Spectroscopy 
1
H NMR spectra were recorded at 300 MHz, 400 MHz, 500 MHz and 600 MHz and 
13
C NMR at 75 MHz, 100 MHz, 125 MHz and 150 MHz on Bruker AMX300, 
AMX400, AMX500 and AMX600 at 25 ºC in a deuterated solvent as described 
below. The chemical shifts (δ) for 1H and 13C are quoted relative to residual signals 
of the solvent on the parts per million (ppm) scale. In the case of multiple amide 
rotamers, only the major rotamer has been assigned. Coupling constants (J values) 
are reported in Hertz (Hz) and are reported as J (H-H) couplings unless otherwise 
stated. Units for optical rotation are 10
-1 
deg cm
2 
g
-
1. Infrared spectra were obtained 
on a Perkin Elmer Spectrum 100 FTIR Spectrometer operating in ATR mode. Mass 
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spectra were obtained at UCL on either a VG70-SE (FAB), Thermo Finnigan 
MAT900Xp (EI and CI) or Waters LCT Premier XE (ES) mass spectrometer. 
Chemicals and Solvents 
Solvents were used as received unless otherwise stated. Petrol refers to petroleum 
ether (b.p. 40-60 ºC). All reagents were purchased from Sigma-Aldrich or Fisher 
Scientific and were used without further purification. Dibenzylcyclooctyne-PEG4-
Fluor-545 65 was purchased from Jena Bioscience GmbH. Octyne 52 was 
synthesised by Antoine Marauani (PhD student, Caddick Group). Bromomaleimide-
dec-biotin 158 was synthesized by Dr. Chris Ryan (Post-Doctoral Research Scientist, 
Caddick Group). 
Cloning and expression of proteins 
Superfolder GFP 29, GFP (T230C, 233Δ) 30, GFP (S147C) 32 and GFP (S147C, 
T230C,233Δ) 55 were cloned and expressed by Paul Moody (PhD Student, Caddick 
Group). Grb2-SH2 (L111C) 124 was obtained from Waksman group.  
The gene for GFP (+CG) 31 and GFP (S147C, +CG) 54 in the vector pNIC28-Bsa4 
were generated as described previously.
149
 All proteins were expressed with 
polyhistidine-tag at the N-terminus. Protein concentration was determined using UV-
absorbance at 280 nm with estimated extinction coefficient generated using ExPASy 
ProtParam tool. 
 The vector was transformed into BL21(DE3)plysS cells, and proteins were 
expressed at 15 °C. Proteins were purified by nickel chromatography, and the buffer 
was exchanged by repeated diafiltration with sodium phosphate (100 mM, pH 8.0) at 
4 °C. Prior to analysis by LCMS, dithiothreitol (10 μL, 340 mM as a solution in 
water, 1000 equivalents per 100 μL of protein (1 mg/mL solution)) was added, the 
mixture incubated at 21 °C for 1 h and excess reducing agent was removed by 
repeated diafiltration with sodium phosphate (100 mM, pH 8.0). 
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Experimental for Chapter 2 
2,5-Dibromohexanediamide 14 70 
 
To a stirring solution of SOCl2 (15.0 mL, 206 mmol) was added adipic acid (5.00 g, 
34.2 mmol) at 21 °C. The reaction mixture was refluxed for 90 min. CHCl3 (20 mL) 
was added to the reaction followed by NBS (14.6 g, 82.2 mmol). The reaction was 
stirred vigorously and 4 drops of HBr (48% aq.) were added. The reaction was then 
heated to reflux for 2 h, cooled to 4 °C and stirred for 30 min. Precipitate from the 
reaction mixture was filtered and washed with Et2O (20 mL). The filtrate was 
concentrated in vacuo to obtain the crude acid chloride. In a separate reaction flask, 
40 mL of NH4OH (25% aq.) was cooled to 4 ºC and crude acid chloride was added 
dropwise over 20 min with rapid stirring. The reaction mixture was further stirred for 
another 1 h. A white solid precipitated was obtained that was filtered and dried in 
vacuo. The crude product was resuspended in H2O (20 mL) and MeOH (20 mL), 
heated to 60 °C and stirred for 30 min. The suspension was cooled, filtered and 
washed with cold MeOH (20 mL) to afford 14 as a while solid (4.13 g, 13.7 mmol, 
40%).  
1H NMR (600MHz, DMSO) δ 7.70 (s, 2H), 7.33 (s, 2H), 4.35 – 4.29 (m, 2H), 2.06-
1.81 (m, 4H); 
13
C NMR (150MHz, DMSO) (Both diastereomers 1:1) δ 169.9 (C), 
169.8 (C), 48.5 (CH), 48.2 (CH), 32.6 (CH2), 32.5 (CH2); IR (solid) υmax 3332, 3176, 
1657, 1443, 1411, 765, 693 cm
-1
; LRMS (m/z) (CI) 305 (
81,81
M
+
, 29), 303 (
81,79
M
+
, 
54), 301 (
79,79
M
+
, 26), 286 (100); HRMS C6H10
79
Br2N2O2 calcd. 300.9187 found 
300.9191 m.p. 192-194 
o
C. 
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Superfolder GFP 29 
149
 
 
Sequence 
MHHHHHHSSGVDLGTENLYFQSMRKGEELFTGVVPILVELDGDVNGHKFSVRGEGEG
DATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGY
VQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHN
VYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSV
LSKDPNEKRDHMVLLEFVTAAGITHGMDELYK (Expected: 29341, Observed 
29345) 
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GFP (+CG) 30 
 
Sequence 
MHHHHHHSSGVDLGTENLYFQSMRKGEELFTGVVPILVELDGDVNGHKFSVRGEGEG
DATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGY
VQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHN
VYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSV
LSKDPNEKRDHMVLLEFVTAAGITHGMDELYKCG (Expected 29519, Observed 
29515) 
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GFP (T230C, 233Δ) 31 
 
Sequence 
MHHHHHHSSGVDLGTENLYFQSMRKGEELFTGVVPILVELDGDVNGHKFSVRGEGEG
DATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGY
VQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNSHN
VYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSV
LSKDPNEKRDHMVLLEFVTAAGICHG (Expectd 28581, Observed 28575) 
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GFP (S147C) 32 
149
 
 
Sequence 
MHHHHHHSSGVDLGTDNLYFQSMRKGEELFTGVVPILVELDGDVNGHKFSVRGEGEG
DATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGY
VQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNCHN
VYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSV
LSKDPNEKRDHMVLLEFVTAAGITHGMDELYK (Expected 29343, Observed 29345) 
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GFP (+CG, N-methylmaleimide) 33  
 
N-methylmaleimide (5 μL, 138 mM solution in DMF, 20 equivalents) was added to a 
solution of GFP (+CG) 30 (100 μL, 1.0 mg/mL) in sodium phosphate (100 mM, pH 
8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at 21 °C for 1 h and 
analysed by LCMS (Expected 29624, Observed 29634) 
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GFP (T230C, N-methylmaleimide) 34  
 
N-methylmaleimide (5 μL, 138 mM solution in DMF, 20 equivalents) was added to a 
solution of GFP (T230C, 233Δ) 31 (100 μL, 1.0 mg/mL) in sodium phosphate (100 
mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at 21 °C for 1 h 
and analysed by LCMS (Expected 28686, Observed 28686). 
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GFP (S147C, N-methylmaleimide) 35 
 
N-methylmaleimide (5 μL, 138 mM solution in DMF, 20 equivalents) was added to a 
solution of GFP (S147C) 32 (100 μL, 1.0 mg/mL) in sodium phosphate (100 mM, 
pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at 21 °C for 1 h and 
analysed by LCMS (Expected 29456, Observed 29454). 
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GFP (+CG, Dha) 39  
 
2,5-Dibromohexanediamide (14, 10 μL, 17 mM solution in DMF, 50 equivalents) 
was added to a solution of GFP (+CG) 30 (1.0 mg/mL) in sodium phosphate (100 
mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at 37 °C for 2 h 
and analysed by LCMS (Expected 29481, Observed 29487). 
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GFP (T230C, Dha) 40  
 
2,5-Dibromohexanediamide (14, 10 μL, 17 mM solution in DMF, 50 equivalents) 
was added to a solution of GFP (T230C, 233Δ) 31 (1.0 mg/mL) in sodium phosphate 
(100 mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at 37 °C 
for 2 h and analysed by LCMS (Expected 28541, Observed 28543). 
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GFP (S147C, Sulf) 42  
 
2,5-Dibromohexanediamide (14, 10 μL, 17 mM solution in DMF, 50 equivalents) 
was added to a solution of GFP (S147C) 32 (1.0 mg/mL) in sodium phosphate (100 
mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at 37 °C for 2 h 
and analysed by LCMS (Expected 29486, Observed 29489). 
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Optimization of GFP (S147C, Sulf) 42 formation 
 
2,5-Dibromohexanediamide 14 (10, 25 or 50 equivalents), as a solution in DMF, was 
added to a solution of GFP (S147C) (100 μL, 1.0 mg/mL) in sodium phosphate (100 
mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at the required 
temperature (4 °C, 21 °C or 37 °C) for the prescribed time (2 h, 5 h or 20 h) and  
analysed by LCMS (Expected Mass: 29566 and 29486). 
10 equivalents, 21 °C 
2 h 
 
 
 
 
5 h 
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20 h 
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25 equivalents, 21 °C 
2 h 
 
 
 
 
5 h 
 
 
127 
 
 
20 h 
 
 
 
50 equivalents, 21 °C 
2 h 
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5 h 
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20 h 
 
 
 
10 equivalents, 4 °C, 20 h 
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25 equivalents, 4 °C, 20 h 
 
 
 
50 equivalents, 4 °C, 20 h 
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50 equivalents, 37 °C, 2 h 
 
 
 
 
 
 
 
132 
GFP (S147C, Sulf) 2-mercaptoethanol conjugate 46  
 
2-Mercaptoethanol (5 μL, 680 mM solution in H2O, 1000 equivalents) was added to 
a solution of GFP (S147C, Sulf) 42 (1.0 mg/mL). The mixture was vortexed for 1 s 
and maintained at 37 °C for 2.5 h and analysed by LCMS (Expected 29563, 
Observed 29566). 
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GFP (S147C, Sulf) thioglucose conjugate 47  
 
Thioglucose (10 or 100 equivalents), as a solution in water, was added to a solution 
of GFP (S147C, Sulf) 42 (100 μL, 1.0 mg/mL) in sodium phosphate (100 mM, pH 
8.0) at 21 °C. The mixture was vortexed for 1s, maintained at the required 
temperature (21 or 37 °C) for 5 h and analysed by LCMS (Expected 29681, 
Observed 29682). 
10 equivalents, 37 °C, 5 h 
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100 equivalents, 21 °C, 5 h 
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GFP (S147C, Sulf) Glutathione conjugate 48 
 
Glutathione (10, 100 or 200 equivalents), as a solution in water, was added to a 
solution of GFP (S147C, Sulf) 42 (100 μL, 1.0 mg/mL) in sodium phosphate (100 
mM, pH 8.0) at 21 °C. The mixture was vortexed for 1s, maintained at the required 
temperature (21 or 37 °C) for the prescribed time (2 h or 5 h) and analysed by LCMS 
(Expected 29792, Observed 29795/29796). 
10 equivalents, 37 °C, 5 h 
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100 equivalents, 21 °C, 5 h  
 
 
 
200 equivalents, 37 °C, 2 h  
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GFP (S147C, Sulf) benzeneselenol conjugate 49 
 
Benzeneselenol (5 μL, 68 mM solution in DMF, 100 equivalents) was added to a 
solution of GFP (S147C, Sulf) 42 (100 μL, 1.0 mg/mL) in sodium phosphate (100 
mM, pH 8.0) at 21 °C. The mixture was vortexed for 1s, maintained at the 37 °C for 
5 h and analysed by LCMS (Expected 29642, Observed 29645). 
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GFP (S147C, Sulf) phthalimide conjugate 50 
 
Potassium phthalimide (10 μL, 340 mM solution in DMF, 1000 equivalents) was 
added to a solution of GFP (S147C, Sulf) 42 (100 μL, 1.0 mg/mL) in sodium 
phosphate (100 mM, pH 8.0) at 21 °C. The mixture was vortexed for 1s and 
maintained at 37 °C for 2.5 h. Excess reagents were removed by repeated 
diafiltration into fresh buffer (100mM sodium phosphate, pH 8.0) using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO) and the mixture analysed by 
LCMS (Expected 29632, Observed 29635). 
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GFP (S147C, Azide) 51 
 
Sodium azide (10 μL, saturated solution in water) was added to a solution of GFP 
(S147C, Sulf) 42 (100 μL, 1.0 mg/mL) in sodium phosphate (100 mM, pH 8.0) at 
21 °C. The mixture was vortexed for 1s, maintained at 37 °C for 2.5 h and analysed 
by LCMS (Expected 29528, Observed 29528). 
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GFP (S147C, azide) octyne conjugate 53 
 
Octyne (52, 10 μL, 34 mM solution in DMF, 100 equivalents) was added to a 
solution of GFP (S147C, azide) 42 (100 μL, 1.0 mg/mL) in sodium phosphate 
(100 mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s and then maintained at 
21 °C for 16 h. Excess reagents were removed by repeated diafiltration into fresh 
buffer (100mM sodium phosphate, pH 8.0) using VivaSpin sample concentrators 
(GE Healthcare, 10,000 MWCO) and the mixture analysed by LCMS (Expected 
29698, Observed 29705). 
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GFP (S147C, +CG) 54 
 
Sequence 
MHHHHHHSSGVDLGTENLYFQSMRKGEELFTGVVPILVELDGDVNGHKFSVRGEGEG
DATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGY
VQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNCHN
VYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSV
LSKDPNEKRDHMVLLEFVTAAGITHGMDELYKCG (Expected 29535, Observed 
29526) 
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GFP (S147C, T230C, 233Δ) 55 
 
Sequence 
MHHHHHHSSGVDLGTENLYFQSMRKGEELFTGVVPILVELDGDVNGHKFSVRGEGEG
DATNGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFARYPDHMKQHDFFKSAMPEGY
VQERTISFKDDGTYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNFNCHN
VYITADKQKNGIKANFKIRHNVEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSV
LSKDPNEKRDHMVLLEFVTAAGICHG (Expected 28597, Observed 28590) 
 
 
 
 
 
143 
GFP (S147C N-methylmaleimide, +CG N-methylmaleimide) 56  
 
 
N-methylmaleimide (5 μL, 6.8 mM solution in DMF, 1 equivalent) was added to a 
solution of GFP (S147C, +CG) 54 (100 μL, 1.0 mg/mL) in sodium phosphate (100 
mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained at 21 °C for 1 h 
and analysed by LCMS (Expected 29744, Observed 29752).  
 
 
 
 
144 
Reaction of GFP (S147C, T230C, 233Δ) 55 with 
N-methylmaleimide 
 
N-methylmaleimide (5 μL, 6.8 mM solution in DMF, 1 equivalent) was added to a 
solution of GFP (S147C, T230C, 233Δ) 55 (100 μL, 1.0 mg/mL) in sodium 
phosphate (100 mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained 
at 21 °C for 1 h and analysed by LCMS (Expected 28701 and 28812, Observed 
28703 and 28804).  
 
 
 
 
145 
GFP (S147C Sulf, +CG Dha) 58  
 
2,5-Dibromohexanediamide (14, 30 μL, 510 mM solution in DMF, 1500 equivalents) 
was added to a solution of GFP (S147C, +CG) 54 (300 μL, 1.0 mg/mL) in sodium 
phosphate (100 mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained 
at 37 °C for 2 h and analysed by LCMS (Expected 29633, Observed 29640). 
 
 
 
 
 
 
 
146 
GFP (S147C Sulf, T230C Dha) 59  
 
2,5-Dibromohexanediamide 14 (30 μL, 17 mM solution in DMF, 50 equivalents) 
was added to a solution of GFP (S147C, T230C, 233Δ) 55 (300 μL, 1.0 mg/mL) in 
sodium phosphate (100 mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, 
maintained at 37 °C for 2 h and analysed by LCMS (Expected 28697, Observed 
28699). 
 
 
 
 
 
 
 
147 
GFP (S147C, +CG) hexanediamide bisthioether 60 
 
2,5-Dibromohexanediamide (14, 30 μL, 17 mM solution in DMF, 50 equivalents) 
was added to a solution of GFP (S147C, +CG) 54 (300 μL, 1.0 mg/mL) in sodium 
phosphate (100 mM, pH 8.0) at 21 °C. The mixture was vortexed for 1 s, maintained 
at 37 °C for 2 h and analysed by LCMS (Expected 29666, Observed 29667). 
 
 
 
 
 
 
 
 
148 
GFP (S147C Azide, +CG Dha) 61  
 
Sodium azide (30 μL, saturated solution in water) was added to a solution of GFP 
(S147C Sulf, +CG Dha) 58 (300 μL, 1.0 mg/mL) in sodium phosphate (100 mM, pH 
8.0) at 21 °C. The mixture was vortexed for 1 s and maintained at 37 °C for 2 h. 
Excess reagents were removed by repeated diafiltration into fresh buffer (100mM 
sodium phosphate, pH 8.0) using VivaSpin sample concentrators (GE Healthcare, 
10,000 MWCO) and the mixture analysed by LCMS (Expected 29675, Observed 
29676). 
 
 
 
 
 
149 
GFP (S147C Azide, T230 Dha) 62  
 
Sodium azide (30 μL, saturated solution in water) was added to a solution of GFP 
(S147C Sulf, T230C Dha) 59 (300 μL, 1.0 mg/mL) in sodium phosphate (100 mM, 
pH 8.0) at 21 °C. The mixture was vortexed for 1 s and maintained at 37 °C for 2 h. 
Excess reagents were removed by repeated diafiltration into fresh buffer (100mM 
sodium phosphate, pH 8.0) using VivaSpin sample concentrators (GE Healthcare, 
10,000 MWCO) and the mixture analysed by LCMS (Expected 28739, Observed 
28736). 
 
 
 
150 
GFP (S147C Azide, +CG Dha 2-mercaptoethanol) conjugate 63  
 
2-mercaptoethanol (2 μL) was added to a solution of GFP (S147C Azide, +CG Dha) 
61 (200 μL, 1.0 mg/mL) in sodium phosphate (100 mM, pH 8.0) at 37 °C. The 
mixture was vortexed for 1 s and maintained at 37 °C for 30 min. Excess reagents 
were removed by repeated diafiltration into fresh buffer (100mM sodium phosphate, 
pH 8.0) using VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO) and 
the mixture analysed by LCMS (Expected 29754, Observed 29753). 
 
 
 
 
 
151 
GFP (S147C Azide Octyne, +CG Dha 2-mercaptoethanol) 
conjugate 64  
 
Octyne 52 (10 μL, 34 mM solution in DMF, 100 equivalents) was added to a solution 
GFP (S147C Azide, +CG Dha 2-mercaptoethanol) conjugate 63 (100 μL, 1.0 
mg/mL) in sodium phosphate (100 mM, pH 8.0) at 21 °C. The mixture was vortexed 
for 1 s and maintained at 21 °C for 16 h. Excess reagents were removed by repeated 
diafiltration into fresh buffer (100mM sodium phosphate, pH 8.0) using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO) and the mixture analysed by 
LCMS (Expected 29845, Observed 29853). 
 
 
 
152 
GFP (S147C Azide dibenzylcyclooctyne-PEG4-Fluor-545, 
T230C Dha) conjugate 66  
 
Dibenzylcyclooctyne-PEG4-Fluor-545 65 (10 μL, 34 mM solution in DMF, 100 
equivalents) was added to a solution of GFP (S147C Azide, T230C Dha) 62 (100 μL, 
1.0 mg/mL) in sodium phosphate (100 mM, pH 8.0) at 21 °C. The mixture was 
vortexed for 1 s, maintained at 21 °C for 4 h. Excess reagents were removed by 
repeated diafiltration into fresh buffer (100mM sodium phosphate, pH 8.0) using 
VivaSpin sample concentrators (GE Healthcare, 10,000 MWCO) and the mixture 
analysed by LCMS (Expected 29675, Observed 29679). 
 
 
 
153 
GFP (S147C Azide dibenzylcyclooctyne-PEG4-Fluor-545, 
T230C Dha 2-mercaptoethanol) conjugate 67 
 
2-Mercaptoethanol (2 μL) was added to a solution of GFP (S147C Azide 
dibenzylcyclooctyne-PEG4-Fluor-545, T230C Dha) conjugate 66 (100 μL, 1.0 
mg/mL) in sodium phosphate (100 mM, pH 8.0) at 21 °C. The mixture was vortexed 
for 1 s, maintained  at 37 °C for 30 min. Excess reagent was removed by repeated 
diafiltration into fresh buffer (100mM sodium phosphate, pH 8.0) using VivaSpin 
sample concentrators (GE Healthcare, 10,000 MWCO) and the mixture analysed by 
LCMS (Expected 29753, Observed 29755). 
 
 
 
154 
Experimental for Chapter 3 
5-(Dodecyldisulfanyl)-2-nitrobenzoic acid 96 
 
To a stirring solution of 5,5'-dithiobis-(2-nitrobenzoic acid) (2.00 g, 4.94 mmol) in 
MeOH (30 mL) at 21 
o
C was added dodecanethiol (591 μL, 2.47 mmol) premixed 
with K2CO3 (340 mg, 2.47 mmol) in a mixture of water (5mL) and MeOH (15 mL). 
The addition of dodecanethiol was carried out dropwise over 20 min followed by 
stirring at 21 
o
C for 4 h. After this, the reaction mixture was concentrated in vacuo 
and diluted with water (25 mL), followed by extraction with EtOAc (2 x 25 mL). The 
organic layers were combined, dried (MgSO4) and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (35% 
EtOAc/petrol) to afford 96 as a pale yellow solid (296 mg, 0.740 mmol, 30%). 
1H NMR (600MHz, MeOD): δ 7.94 (d, 1H, J = 8.4), 7.70 (d, 1H, J = 1.8 ), 7.63 (dd, 
1H, J = 8.4 and 1.8), 2.80 (t, 2H, J = 7.2), 1.68 (quintet, 2H, J = 7.8), 1.40-1.38 (m, 
2H), 1.31-1.24 (m, 16H), 0.90 (t, 3H, J = 7.2); 
13C NMR (125MHz, MeOD) δ 173.0 
(C), 147.4 (ArC), 146.7 (ArC), 130.8 (ArC), 129.1 (ArC), 127.1 (ArC), 125.8 (ArC), 
40.0 (CH2), 33.1 (CH2), 30.8 (CH2), 30.7 (CH2), 30.6 (CH2), 30.5 (CH2), 30.3 (CH2), 
29.9 (CH2), 29.4 (CH2), 28.9 (CH2), 23.8 (CH2), 14.5 (CH3); IR (solid) υmax 2900, 
2851, 1464 cm
-1
; LRMS (m/z) (ES+) 422 ([M+Na]
+
, 100); HRMS C19H29O4NS2Na 
calcd. 422.1430 found 422.1635; m.p. 42-44 
o
C. 
 
 
 
155 
Tris(dimethylamino) dodecanethiophosphonium 
tetrafluoroborate 101 
 
To a stirring solution of dodecanethiol (2.50 g, 12.3 mmol) in THF (35 mL) cooled 
to -40 °C was added t-butylhypochlorite (1.51 mL, 12.9 mmol). The reaction was 
stirred for 10 min followed by addition of tris(dimethylaminophosphine) (2.24 mL, 
12.3 mmol). After stirring for 5 min, a white precipitate was observed. The reaction 
was diluted with water (25 mL) and washed with Et2O (2 x 25 mL). The aqueous 
layer was treated with NaBF4 (2.00 g, 18.2 mmol) in water (25 mL). The solution 
became clear and the aqueous layer was extracted with DCM (3 x 25 mL), dried 
(MgSO4) and concentrated in vacuo. The crude product was purified by 
recrystallization from DCM/Et2O to afford 101 as a white solid (2.80 g, 6.20 mmol, 
50%).  
1
H NMR (600MHz, CDCl3) δ 2.94-2.90 (m, 2H), 2.82 (d, 18 H, JH-P = 11.2), 1.68 
(quintet, 2H, J = 7.8), 1.35 (quintet , 2H, J = 7.2), 1.26-1.21 (m, 16H), 0.83 (t, 3H, J 
= 7.1); 
13
C NMR (150MHz, CDCl3) δ 37.5 (d, CH3, JC-P = 3.8), 32.0 (CH2), 31.1 (d, 
CH2,
 
JC-P = 4.2 ), 30.3 (CH2), 30.2 (CH2), 29.7 (d, CH2, JC-P = 1.8), 29.6 (CH2), 29.5 
(CH2), 29.4 (CH2), 29.1 (CH2), 28.5 (CH2), 22.8 (CH2), 14.2 (CH3); 
31
P NMR 
(121MHz, CDCl3) δ 66.9; IR υmax (solid) 2923, 2854, 1468, 1300, 1297, 1171, 1049, 
1036 cm
-1
; LRMS (m/z) (ES+) 364 (M
+
, 100); HRMS C18H43N3PS calcd. 364.2915, 
found 364.2908; m.p. 126-128 
o
C. 
  
 
 
 
156 
(R)-5-((2-((tert-butoxycarbonyl)amino)-3-methoxy-3-
oxopropyl)disulfanyl)-2-nitrobenzoic acid 108 
 
To a stirring solution of 5,5'-dithiobis-(2-nitrobenzoic acid) (1.26 g, 3.19 mmol) in 
DMF (10 mL) and buffer (100 mM sodium phosphate, pH 8.0) (10 mL) at 21 
o
C was 
added a solution of N-Boc-Cys-OMe 107 (250 mg, 1.06 mmol) in DMF (2 mL) 
dropwise over 30 min. The reaction was stirred at 21 
o
C for 10 min. The pH was 
adjusted to 5 with HCl (1M), followed by extraction with EtOAc (2 x 25 mL). The 
organic layer was washed with buffer (100 mM sodium phosphate, pH 8.0) (2 x 25 
mL). The aqueous layers were combined and the pH was adjusted to pH 4 by the 
addition of HCl (1M) followed by extraction with EtOAc (2 x 25 mL). The organic 
layers were combined and washed with saturated aqueous LiCl (2 x 25 mL), dried 
(MgSO4) and concentrated in vacuo to afford 108 as a yellow oil (150 mg, 
0.350 mmol, 33%).  
1
H NMR (600MHz, MeOD) δ 7.92 (d, 1H), 7.89-7.88 (m, 1H), 7.85-7.83 (m, 1H), 
4.43 (dd, 1H, J = 9.0 and 4.2), 3.70 (s, 3H), 3.26 (dd, 1H, J = 13.8 and 4.5), 3.07 (dd, 
1H, J = 14.2 and 8.9), 1.42 (s, 9H); 
13C NMR (150MHz, MeOD) δ 173.1 (C), 168.0 
(C), 157.7(C), 147.7 (ArC), 145.6 (ArC), 130.7 (ArC), 129.5 (ArC), 127.6 (ArC), 
125.9 (ArC), 81.0 (C), 54.2 (CH), 53.0 (CH3), 41.2 (CH2), 28.7 (CH3); IR υmax (oil) 
2983, 1709, 1601, 1521, 1360, 1159 cm
-1
; LRMS (ES+) (m/z) 455([M+Na]
+
, 30), 
311 (100); HRMS C16H20N2O8NaS2 calcd. 455.0559, found 455.0532;
 
[α]D
20
 +56.6 (c 
1.0, MeOH); m.p. 89-91 
o
C. 
 
 
157 
Methyl 2-((tert-butoxycarbonyl)amino)acrylate 110 
 
Method 1: To a stirring solution of disulfide 108 (30.0 mg, 0.069 mmol) in DMF (6 
mL) and buffer (100 mM sodium phosphate, pH 8.0) (20 mL) at 21 
o
C was added 
tris(dimethylamino)phosphine (25 μL, 0.14 mmol). The reaction was stirred at 21 oC 
for 4 h. The reaction mixture was extracted with EtOAc (2 x 25 mL). The organic 
layers were combined and washed with saturated aqueous LiCl solution (3 x 25 mL), 
saturated aqueous NaCl (25 mL), dried (MgSO4) and concentrated in vacuo. The 
crude residue was purified by flash column chromatography on a silica gel (5% 
EtOAc/Petrol) to afford 110 as a colourless oil (7.00 mg, 0.034 mmol, 50%). 
Method 2: To a stirring solution of disulfide 108 (30.0 mg, 0.069 mmol) in DMF (6 
mL) and buffer (70 mM CHES/MES, pH 9.5) (20 mL) at 21 
o
C was added 
tris(dimethylamino)phosphine (25.0 μL, 0.140 mmol). The reaction was stirred at 21 
o
C for 4 h. The reaction mixture was extracted with EtOAc (2 x 25 mL). The organic 
layers were washed with saturated aqueous LiCl solution (3 x 25 mL), saturated 
aqueous NaCl (25 mL), dried (MgSO4) and concentrated in vacuo. The crude residue 
was purified by flash column chromatography on a silica gel (5% EtOAc/Petrol) to 
afford 110 as a colourless oil (6.30 mg, 0.031 mmol, 45%). 
1
H NMR (500MHz, CDCl3) δ 7.00 (s, 1H), 6.15 (s, 1H), 5.72 (s, 1H), 3.82 (s, 3H), 
1.48 (s, 9H); 
13
C NMR (125MHz, CDCl3) δ 164.6 (C), 152.6 (C), 131.4 (CH), 105.3 
(CH), 80.8 (CH3), 52.9 (CH3), 28.3 (CH3); IR υmax (oil) 3423, 2979, 1717, 1630 cm
-1
; 
LRMS (m/z) (EI) 201 (M
+
, 23), 174 (40), 145 (100); HRMS C9H15O4N calcd. 
201.0996, found 201.0991.  
 
 
 
 
158 
GFP (S147C, 5-mercapto-2-nitrobenzoic acid)disulfide 112 
 
To a solution of GFP (S147C) 32 (100 μL, 1 mg/ml, 100 mM sodium phosphate, pH 
8.0) at 4 °C was added 5,5'-dithiobis-(2-nitrobenzoic acid) (5 μL, 0.67 mM solution 
in DMF, 1 equivalent). The mixture was vortexed for 1 s, maintained at 4 °C for 16 h 
and analysed by LCMS (Expected 29543, Observed 29544).  
 
 
 
 
 
159 
GFP (S147C, thiophosphonium) 113 and GFP(S147C) Dimer 
114 
 
To a solution of GFP (S147C, 5-mercapto-2-nitrobenzoic acid) disulfide 112 (100 
μL, 5 mg/ml, 100 mM sodium phosphate, pH 8.0) was added 
tris(dimethylamino)phosphine (5 μL, 205 mM solution in DMF, 60 equivalents) at 
4 °C. The reaction was maintained at 21 °C for 2 h and analysed by LCMS 
(Expected 29508 and 58690, Observed 29516 and 58740).  
 
 
 
 
 
 
160 
Tris(dimethylamino) benzenethiophosphonium 
tetrafluoroborate 120 
 
To a stirring solution thiophenol (1.00 g, 9.09 mmol) in THF (35 mL) cooled to 
-40 °C was added t-butylhypochlorite (1.14 mL, 9.54 mmol). The reaction was 
stirred for 10 minutes followed by addition of tris(dimethylaminophosphine) 
(1.65 mL, 9.09 mmol). After stirring for 5 minutes, a white precipitate was observed. 
The reaction was diluted with water (25 mL) and washed with Et2O (2 x 25 mL). The 
aqueous layer was treated with NaBF4 (2.00 g, 1.82 mmol) in water (25 mL). The 
solution became clear and the aqueous layer was extracted with DCM (3 x 25 mL), 
dried (MgSO4) and concentrated in vacuo. The crude product was purified by 
recrystallization from DCM/Et2O to afford 120 as a white solid (600 mg, 1.67 mmol, 
18%).  
1
H NMR (600MHz, CDCl3) δ 7.59-7.57 (m, 2H), 7.51-7.45 (m, 3H), 2.73 (d, 18 H, J 
= 10.8); 
13
C NMR (150MHz, CDCl3) δ 136.9 (d, ArC,
 
JC-P = 4.6), 131.7 (d, ArC,
 
JC-P 
= 3.6), 130.8 (d, ArC,
 
JC-P = 3), 121.4 (d, ArC,
 
JC-P = 6.8), 37.8 (d, CH3,
 
JC-P = 3.2); 
31
P NMR (121MHz, CDCl3) δ 61.9; IR υmax (solid) 2923, 1473, 1297, 1171, 1046, 
985 cm
-1
; LRMS (m/z) (ES+) 272 (M
+
, 100); HRMS C12H23N3PS calcd. 272.1350, 
found 272.1346; m.p. 98-100 
o
C. 
 
 
 
 
 
161 
1-Bromododecane 122 
 
To a stirring solution of 5-(dodecyldisulfanyl)-2-nitrobenzoic acid 96 (50.0 mg, 
0.125 mmol) in DMF (1.50 mL) at 21 °C was added tris(dimethylamino)phosphine 
68 (50.0 μL, 0.275 mmol). The solution turned red within 1 min and NaBr (64.0 mg, 
0.625 mmol) in water (0.5 mL) was subsequently added. The reaction was heated to 
60 °C for 6 h. The aqueous reaction mixture was extracted with EtOAc (2 x 10 mL). 
The organic layer was then washed with aqueous LiCl (3 x 10 mL), aqueous NaCl 
(15 mL), dried (MgSO4) and concentrated in vacuo. The residue was purified by 
flash column chromatography on a silica gel (1% to 5% EtOAc/Petrol) to afford 122 
as a colourless oil (5.00 mg, 0.021 mmol, 17%). 
1
H NMR (600MHz, CDCl3) δ 3.40 (t, 2H, J = 6.9), 1.85 (quintet, 2H, J = 6.9), 1.44-
1.39 (m, 2H), 1.29-1.26 (m, 16H), 0.88 (t, 3H, J = 6.8); 
13
C NMR (150MHz, CDCl3) 
δ 34.2 (CH2), 33.0 (CH2), 32.0 (CH2), 29.8 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 
(CH2), 29.5 (CH2), 28.9 (CH2), 28.3 (CH2), 22.8 (CH2), 14.3 (CH3); IR υmax (oil) 
2923, 2853, 1465, 906 cm
-1
; LRMS (m/z) (EI) 250 (
81
M+, 4), 248 (
79
M+, 4), 137 
(95), 135 (100); HRMS C12H25
79
Br calcd. 248.1134, found 248.1136.    
 
 
 
 
 
 
 
 
 
162 
Experimental for Chapter 4 
Grb2-SH2 Domain (L111C) 124 
 
Sequence 
MGIEMKPHPWFFGKIPRAKAEEMLSKQRHDGAFLIRESESAPGDFSLSVKFG 
NDVQHFVCRDGAGKYFLWVVKFNSLNELVDYHRSTSVSRNQQIFLRDIEQV 
PQQPTYVQAGSRSHHHHHH (Expected 14170 Observed 14164). 
 
 
 
 
 
 
 
 
 
 
 
163 
Grb2-SH2 (L111C, N-methylmaleimide) 126 
 
To a solution of Grb2-SH2 (L111C) 124 (100 μL, 1 mg/ml, 100 mM sodium 
phosphate, pH 8.0) at 4 °C was added bromo-N-methylmaleimide 125 (5 μL, 2.82 
mM solution in DMF, 1 equivalent). The mixture was vortexed for 1 s, maintained at 
4 °C for 1 h then analysed by LCMS (Expected 14275, Observed 14280). 
 
 
 
 
 
 
 
 
 
164 
3-Bromo-1-methyl-1H-pyrrole-2,5-dione 125 
47
 
 
To a stirring solution of N-methylmaleimide 137 (500 mg, 4.50 mmol) in MeOH 
(22.5 mL) at 21 °C was added bromine (520 μL, 10.0 mmol) dropwise. The reaction 
mixture was stirred at 21 °C for 24 h. The reaction mixture was concentrated 
in vacuo and the crude product was dissolved in THF (20 mL). To this was added 
NEt3 (0.800 mL, 5.85 mmol) and the reaction was stirred for 24 h at 21 °C. The 
reaction mixture was concentrated in vacuo and the crude residue was purified by 
flash column chromatography on silica gel (30% EtOAc/Petrol) to afford 125 as a 
pale white powder (0.760 g, 4.00 mmol, 89%). 
1
H NMR (500MHz, CDCl3) δ 6.90 (s, 1H), 3.09 (s, 3H); 
13
C NMR (125MHz, 
CDCl3) δ 168.6 (C), 165.4 (C), 131.9 (CH), 131.4 (C), 24.7 (CH3); IR υmax (solid) 
3106, 1777, 1708, 1590, 1440, 1391, 1231, 970 cm
-1
; LRMS (m/z) (EI) 192 (
81
M
+
, 
99), 190 (
79
M
+
, 100);  HRMS C5H5O2N
79
Br calcd. 189.9504, found 189.9505; m.p. 
77-79 
o
C.    
 
 
 
 
 
 
 
 
165 
(R)-Methyl 2-((tert-butoxycarbonyl)amino)-3-((1-methyl-2,5-
dioxo-2,5-dihydro-1H-pyrrol-3-yl)thio)propanoate 130 
47
 
 
To a stirring solution of N-Boc-Cys-OMe 107 (320 mg, 1.36 mmol) and NaOAc (820 
mg, 4.08 mmol) in MeOH (10 mL) at 21 °C was added a solution of 125 (258 mg, 
1.36 mmol) in MeOH (10 mL) over a period of 10 min. The reaction mixture was 
concentrated in vacuo and the crude residue was purified by column chromatography 
(10% to 30% EtOAc/Petrol) to afford 130 as a pale white powder (393 mg, 1.14 
mmol, 84%). 
1
H NMR (600 MHz, CDCl3) δ 6.29 (s, 1H), 5.41 (d, 1H, J = 6.5), 4.69-4.67 (m, 1H), 
3.81 (s, 3H), 3.49 (dd, 1H, J = 13.5 and 5.0), 3.37 (dd, 1H, J = 13.5 and 5.0), 3.02 (s, 
3H), 1.46 (s, 9H); 
13
C NMR (125 MHz, CDCl3) δ 170.5 (C), 169.8 (C), 168.0 (C), 
155.3 (C),  150.3 (C), 118.7 (CH), 81.2 (C), 53.5 (CH3), 53.0 (CH), 34.1 (CH2), 28.6 
(CH3), 24.4 (CH3); IR υmax (solid) 3368, 2977, 1746, 1695, 1162 cm
-1
; LRMS (m/z) 
(ES+) 367 ([M+Na]
+
, 46), 344 (M
+
, 100); HRMS C14H20N2O6NaS calcd. 367.0940, 
found 367.0931; [α]D
20
 -18.6 (c 1.0, MeOH); m.p. 101-103 °C. 
 
 
 
 
 
 
166 
(2R,2'R)-dimethyl 3,3'-disulfanediylbis(2-((tert-
butoxycarbonyl)amino) propanoate) 139 
 
To a stirring solution of N-Boc-Cys-OMe 107 (55.0 mg, 0.233 mmol) in MeOH (5 
mL) at 21 °C was added DMSO (150 μL) and a catalytic amount of I2. The reaction 
mixture was stirred for 30 min at 21 °C and then diluted with DCM (20 mL) 
followed by washing with saturated Na2S2O5 (20 mL) and brine (20 mL). The 
organic layer was separated and dried (MgSO4), filtered and concentrated in vacuo to 
afford 139 as a white powder (53.0 mg, 0.110 mmol, 97%).  
1
H NMR (600MHz, CDCl3) δ 5.38 (d, 2H, J = 6.3), 4.61-4.60 (m, 2H), 3.76 (s, 6H), 
3.16-3.15 (m, 4H), 1.41 (s, 18H); 
13
 C NMR (150MHz, CDCl3) δ 171.3 (C), 155.2 
(C), 80.4 (CH3), 52.86 (CH3), 52.8 (CH), 41.3 (CH2), 28.4 (CH3); IR υmax (solid) 
3363, 2979, 1744, 1697, 1366 cm
-1
; LRMS (m/z) (ES+): 491 ([M+Na]
+
,100); HRMS 
C18H32N2O8NaS2 calcd. 491.1498, found 491.1497; [α]D
22
 -4.8 (c 0.1, CHCl3); m.p. 
38-40 °C. 
 
 
 
 
 
 
 
 
 
167 
Grb2-SH2 (L111C, N-methylmaleimide, Sulfite) 155 
 
To a solution of Grb2-SH2 (L111C, N-methylmaleimide) 126 (100 μL, 1 mg/ml, 100 
mM sodium phosphate, pH 8.0) at 4 °C was sodium sulfite (5 μL, 28.2 mM solution 
in water, 10 equivalents). The mixture was vortexed for 1 s, maintained at 21 °C for 
2 h and analysed by LCMS (Expected 14355, Observed 14356).  
 
 
 
 
 
 
 
 
168 
7-methyl-1,4-dithia-7-azaspiro[4.4]nonane-6,8-dione 155 
 
To a stirring solution of thiomaleimide 130 (40.0 mg, 0.211 mmol) in DMF (1.5 mL) 
and buffer (100 mM sodium phosphate, pH 8.0) (13 mL) at 21 °C was added 1,2-
ethanedithiol (52.0 mg, 0.620 mmol) in  DMF (1.5 mL). The reaction was heated at 
37 °C for 24 h. The reaction mixture was extracted with EtOAc (2 x 25 mL). The 
organic layers were combined and washed with saturated aqueous LiCl (3 x 25 mL), 
saturated aqueous NaCl (25 mL), dried (MgSO4) and concentrated in vacuo. The 
residue was purified by flash column chromatography on silica gel (10% to 30% 
EtOAc/Petrol) to afford a white solid (40.0 mg, 0.200 mmol, 95%). 
1
H NMR (600 MHz, CDCl3) δ 3.77-3.71 (m, 2H), 3.59-3.52 (m, 2H), 3.26 (s, 2H), 
3.02 (s, 3H); 
13
C NMR (150 MHz, CDCl3) δ 178.1 (C), 173.1 (C), 60.0 (C), 42.2 
(CH2), 41.1 (CH2), 25.7 (CH3); IR (solid) υmax 2935, 1736, 1434, 1376, 1285, 1242 
cm
-1
; LRMS (m/z) (ES+) 203 (M
+
, 54), 144 (100); HRMS C7H9NO2S2 calcd. 
203.0069, found 203.0067; m.p. 71-73 
o
C.    
 
 
 
 
 
 
 
 
 
169 
6-Methyldihydro-4aH-[1,4]dithiino[2,3-c]pyrrole-5,7(6H,7aH)-
dione 156 
 
To a stirring solution of bromo-N-methylmaleimide 125 (40.0 mg, 0.210 mmol) in a 
mixture of DMF (1.50 mL) and buffer (100 mM sodium phosphate, pH 8.0) (13 mL) 
at 21 °C was added 1,2-ethanedithiol (20.0 mg, 0.210 mmol) in  DMF (1.50 mL). 
The reaction mixture was heated at 37 °C for 90 min and then extracted with EtOAc 
(2 x 25 mL). The organic layers were combined and washed with saturated aqueous 
LiCl (3 x 25 mL), saturated aqueous NaCl (25 mL), dried (MgSO4), concentrated in 
vacuo and the crude residue purified by flash column chromatography on silica gel 
(10% to 30% EtOAc/petrol) to afford 156 as a white solid (15.0 mg, 0.070 mmol, 
35%). 
1
H NMR (CDCl3, 600 MHz) δ 4.05 (s, 2H), 3.10 (s, 3H), 2.88-2.79  (m, 4H); 
13
C 
NMR (CDCl3, 150 MHz) δ 174.3 (C), 40.8 (CH3), 25.8 (CH), 24.8 (CH2); IR υmax 
(solid) 2985, 1737, 1447, 1373 cm
-1
; LRMS (m/z) (ES+) 203 (M
+
, 100); HRMS 
C7H9NO2S2 calcd. 203.0069, found 203.0070; m.p. 69-71 
o
C.    
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GFP (S147C, biotin-dec-maleimide) 159 
 
To a solution of GFP (S147C) (100 μL, 1 mg/ml, 100 mM sodium phosphate, pH 
8.0) at 4 °C was added bromomaleimide-dec-biotin 158 (5 μL, 2.82 mM solution in 
DMF, 1 equivalent). The mixture was vortexed for 1 s, maintained at 4 °C for 1 h 
then analysed by LCMS (Expected 29823, Observed 29816). 
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